VectivBio Holding (VECT) 6-K 13 Oct 22 2022 Q2 VectivBio Reports Positive Interim Clinical Data from Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2022
Document Information [Line Items]
Document Type	6-K
Document Period End Date	Jun. 30, 2022
Current Fiscal Year End Date	--12-31
Entity Registrant Name	VECTIVBIO HOLDING AG
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001836379

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Other Comprehensive Loss - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue from contracts with customers	$ 25,879
Research and development expenses	(37,511)	(26,494)
General and administrative expenses	(19,290)	(19,097)
Operating loss	(30,922)	(45,591)
Financial income	18
Financial expense	(622)	(23)
Foreign exchange differences, net	1,126	496
Loss before income taxes	(30,400)	(45,118)
Income taxes	(26)
Net loss	(30,426)	(45,118)
OTHER CONSOLIDATED COMPREHENSIVE INCOME OR LOSS, NET OF INCOME TAX
Remeasurement of net pension liabilities	830	508
Total items that will not be reclassified subsequently to profit or loss	830	508
Exchange differences arising on translation of foreign operations	(3,448)	(113)
Total items that may be reclassified subsequently to profit or loss	(3,448)	(113)
Total other comprehensive gain /(loss), net of income tax	(2,618)	395
Total comprehensive loss	$ (33,044)	$ (44,723)
LOSS PER SHARE
Basic net loss per share (in USD)	$ (0.86)	$ (2.26)
Diluted net loss per share (in USD)	$ (0.86)	$ (2.26)

Consolidated and carve-out stat

Consolidated and carve-out statements of financial position - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
NON-CURRENT ASSETS
Property, plant and equipment	$ 16	$ 51
Goodwill	894	925
Intangible assets	24,371	25,122
Right-of-use assets	220	291
Financial assets	59	61
Non-current assets	25,560	26,450
CURRENT ASSETS
Other current receivables	1,206	777
Other current assets	9,101	6,597
Cash and cash equivalents	142,144	102,707
Total current assets	152,451	110,081
Total assets	178,011	136,531
EQUITY
Share capital	2,661	1,935
Treasury shares	(581)	(35)
Reserves	292,315	246,815
Accumulated losses	(152,569)	(132,716)
Total equity	141,826	115,999
NON-CURRENT LIABILITIES
Lease liabilities	89	158
Net pension liabilities	2,436	3,190
Warrant liability	1,124	0
Total non-current liabilities	3,649	3,348
CURRENT LIABILITIES
Trade payables	12,527	8,595
Accrued expenses	14,944	8,339
Deferred revenue	3,488	0
Other current liabilities	1,445	116
Lease liabilities	132	134
Total current liabilities	32,536	17,184
Total liabilities	36,185	20,532
Total equity and liabilities	$ 178,011	$ 136,531

Consolidated and carve-out st_2

Consolidated and carve-out statements of changes in equity - USD ($) $ in Thousands	Total	Share capital	Capital Reserves (Reserves)	Foreign exchange (FX) translation (Reserves)	Accumulated losses	Treasury shares [member]
Balance at beginning of year at Dec. 31, 2020	$ 32,238	$ 1,409	$ 100,904	$ 1,029	$ (71,065)	$ (39)
Net loss	(45,118)				(45,118)
Other comprehensive income/(loss)	395			(113)	508
Total comprehensive loss	(44,723)			(113)	(44,610)
Share capital increase (Note 18)	154,125	486	153,639
Share based payments (Note 11)	11,801				11,801
Transaction costs due to capital increase	(13,039)		(13,039)
Total balance at end of the year at Jun. 30, 2021	140,402	1,895	241,503	916	(103,874)	(39)
Balance at beginning of year at Dec. 31, 2021	115,999	1,935	244,933	1,882	(132,716)	(35)
Net loss	(30,426)				(30,426)
Other comprehensive income/(loss)	(2,618)			(3,448)	830
Total comprehensive loss	(33,044)			(3,448)	(29,596)
Share capital increase (Note 18)	53,955	511	53,444			(215)
Share based payments (Note 11)	9,412				9,412	(331)
Allocatiom of treasury shares to employees (note 11)					331	(331)
Issue of treasury shares		215				(215)
Transaction costs due to capital increase	(4,496)		(4,496)
Total balance at end of the year at Jun. 30, 2022	$ 141,826	$ 2,661	$ 293,881	$ (1,566)	$ (152,569)	$ (581)

Consolidated and carve-out st_3

Consolidated and carve-out statements of cash flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of cash flows [abstract]
Net loss	$ (30,426)	$ (45,118)
Adjustments for:
Financial income	(18)	0
Financial expense	618	23
Change in fair value of warrants	4	0
Depreciation and amortization expenses	121	152
Revaluation on contingent consideration liabilities	0	860
Share-based payments	9,412	11,801
Group's pension expense	175	92
Net foreign exchange differences	(2,993)	(945)
Changes in working capital:
–(Increase)/Decrease in other current receivables	(449)	365
–(Increase) in other current assets	(2,061)	(1,033)
–Increase/(Decrease) in trade payables	4,210	(6,051)
–Increase in accrued expenses	6,865	2,856
Increase in deferred revenue	3,488	0
–Increase/(Decrease) in other current liabilities	1,333	39
–Interest paid	(61)	(24)
Interest received	18	0
Cash flows from (used in) operating activities	(9,764)	(36,983)
Payments for property, plant and equipment	(17)	(33)
Payments to security deposit	(2)	(1)
Cash flow used in investing activities	(19)	(34)
Share capital increase	53,955	154,125
Transaction costs due to capital increase	(4,496)	(12,566)
Transaction costs due to Kreos Loan agreement	(100)	0
Lease principal payments	(67)	(68)
Cash flow provided by financing activities	49,292	141,491
Net increase in cash and cash equivalents	39,509	104,474
Cash and cash equivalents at beginning of the year	102,707	40,172
Net effect of exchange rate changes on cash and cash equivalents	(72)	(36)
Cash and cash equivalents at end of the year	$ 142,144	$ 144,610

Organization and business

Organization and business	6 Months Ended
	Jun. 30, 2022
Organization And Business [Abstract]
Organization and business	1. Organization and business VectivBio Holding AG (the “Company”) is a Swiss stock corporation whose registered office is at Aeschenvorstadt 36, Basel, Switzerland. The Company was incorporated on May 22, 2019, in Switzerland. It is subject to provisions of the articles of incorporation and to article 620 et seq. of the Swiss Code of Obligations, which describes the legal requirements for corporations (“Aktiengesellschaften”). The Company, and its five wholly owned subsidiaries, VectivBio AG, Basel (Switzerland), VectivBio Comet AG, Basel (Switzerland), GlyPharma Therapeutic Inc., Montreal (Canada), Comet Therapeutics Inc and VectivBio Inc. (USA) (collectively, the “Group”), is a global biotechnology group committed to making a difference in the lives of patients living with serious rare conditions. The Group’s mission is to use scientific innovation to target the biological root causes of serious rare conditions to achieve disease modification. The Group’s lead program, Apraglutide, is a next-generation glucagon-like peptide-2 (“GLP-2”) On April 9, 2021, VectivBio Holding AG closed its initial public offering of 8,625,000 ordinary shares, at a public offering price of USD 17.00 per share. The gross proceeds from the offering were USD 146.6 million. The Company’s ordinary shares began trading on the Nasdaq Global Market under the ticker symbol “VECT”. These unaudited interim condensed consolidated financial statements were authorized for issuance by the Board of Directors of the Company on October 1 2

Significant changes in the curr

Significant changes in the current reporting period	6 Months Ended
	Jun. 30, 2022
Disclosure Of Significant Changes In The Current Reporting Period [Abstract]
Significant changes in the current reporting period	2. Significant changes in the current reporting period The financial position and performance of the Group was particularly affected by the following events and transactions during the six-months • On March 30, 2022, the Company entered into a partnering agreement (the “Agreement”) with Asahi Kasei Pharma Corporation (“AKP”). Under the Agreement, the Company has granted an exclusive license to AKP, with the right to sublicense in multiple tiers, to develop, commercialize and exploit products derived from the Company’s lead product candidate, Apraglutide, within the territory of Japan. The Company and AKP will form a joint steering committee to handle development and regulatory plans, and AKP’s activities under the agreement will be conducted in partnership with the Company. The Company retains all rights to Apraglutide not granted to AKP. • On March 26, 2022, the Company entered into a note financing agreement (the “Loan”) with Kreos Capital VI (UK) Limited (“Kreos”). The Loan is structured to provide the EUR equivalent of up to USD 75.0 million in borrowing capacity, the master loan line (“MLL”) comprising two loan facilities of which EUR equivalent of USD 18.75 million is to be a convertible loan line, (the “Convertible Loan”). The remainder of the MLL, is a term loan of EUR equivalent of USD 56.25 million which is to be drawn down at the same time as the convertible loan line in three tranches. As additional consideration for the Loan, Kreos received a fee of USD 750 thousand, as well as a warrant to purchase 324,190 of the Company’s ordinary shares at a price per ordinary share equal to the volume weighted average price per share for the 30-day 30-day The Loan contains customary affirmative and negative covenants. The affirmative covenants include, among others, administrative and reporting requirements subject to certain exceptions and materiality thresholds. The negative covenants include, among others, limitations on the Company’s ability to, subject to certain exceptions, incur additional debt. Additional information about this financing arrangement is disclosed in Note 18. • On June 14, 2022, the Company entered into an Underwriting Agreement with SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and sell, in an underwritten public offering, an aggregate of 5,715,000 ordinary shares with a nominal value of CHF 0.05 per share at a public offering price of USD 5.25 per share. In addition, the Company granted the Underwriters an option for 30 days to purchase up to an additional 857,250 ordinary shares with a nominal value of CHF 0.05 per share at a public offering price of USD 5.25 per share. • On June 17, 2022, the Company issued from authorized share capital and sold 5,715,000 ordinary shares with a nominal value of CHF 0.05 per share to the underwriters. On June 23, 2022, the Company issued from authorized share capital and sold additional 752,688 ordinary shares with a nominal value of CHF 0.05 per share to the underwriters pursuant to the partial exercise of the underwriters’ previously granted option to purchase additional ordinary shares. The aggregate gross proceeds of the public offering amounted to USD 34 million, before deducting underwriting discounts and commissions and other offering expenses. • On June 14, 2022, the Company entered into a Subscription and Share Purchase Agreement (“Purchase Agreement”) with Forbion Growth Opportunities Fund II Coöperatief U.A., represented by Forbion Growth II Management B.V. (“Forbion”), pursuant to which Forbion agreed to purchase, and the Company agreed to sell an aggregate of 3,478,260 ordinary shares with a nominal value of CHF 0.05 per share at a price of USD 5.75 per share, for gross proceeds of USD 20 million, in a private placement. The 3,478,260 ordinary shares consisted of 425,252 ordinary shares issued from authorized share capital on June 23, 2022 and 3,053,008 treasury shares sold to Forbion on June 27, 2022.

Basis of preparation of half-ye

Basis of preparation of half-year condensed consolidated financial statements	6 Months Ended
	Jun. 30, 2022
Disclosure Of Interim Financial Reporting [Abstract]
Basis of preparation of half-year condensed consolidated financial statements	3. Basis of preparation of half-year condensed consolidated financial statements These unaudited interim condensed six-months Interim Financial Reporting They do not include all of the information required in annual financial statements in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and should be read in conjunction with the consolidated and carve-out The accounting policies adopted are consistent with those of the previous financial year and with the corresponding interim reporting period, except for the estimation of income tax and the adoption of new and amended standards as set out below.

Summary of selected significant

Summary of selected significant accounting policies	6 Months Ended
	Jun. 30, 2022
Disclosure of initial application of standards or interpretations [abstract]
Summary of selected significant accounting policies	4. Summary of selected significant accounting policies The Group’s significant accounting policies are set out in Note 2 to the consolidated and carve-out New and amended Standards and Interpretations that are mandatorily effective for the current year The following standards and interpretations apply for the first time to financial reporting periods commencing on or after January 1, 2022: Title Effective Date Amendments to IAS 16 – Property, Plant and Equipment: Proceeds before intended use January 1, 2022 Amendments to IFRS 3 – Reference to the Conceptual Framework January 1, 2022 Amendments to IAS 37 – Onerous Contracts – Cost of Fulfilling a Contract January 1, 2022 Annual Improvements to IFRS 9 Financial Instruments – clarifies which fees should be included in the 10% test for derecognition of financial liabilities. January 1, 2022 Annual Improvements to IFRS 16 Leases – amendment to remove any confusion about the treatment of lease incentives. January 1, 2022 The adoption of such standards did not have a significant impact on the unaudited interim condensed consolidated statements of financial position or statements of operations and other comprehensive loss of the Group. New accounting policies applied in the preparation of the unaudited interim condensed consolidated financial statements as of and for the six-months Revenue recognition Our revenue is derived from contracts with customers in accordance with IFRS 15, mainly from the Agreement with AKP (Note 2 and 8). Based on IFRS 15, we have performed the following steps in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under this agreement: 1. Identification of the promised goods or services in the contract; 2. Determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; 3. Measurement of the transaction price, including the constraint on variable consideration; 4. Allocation of the transaction price to the performance obligations; and 5. Recognition of revenue when each performance obligation is satisfied. For the licensing agreement we have considered a variety of factors in determining the appropriate estimates and assumptions, such as whether the elements within the agreement are distinct performance obligations, whether there are observable standalone selling prices, and whether the customer has right to use or a right to access a license. We have evaluated each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. With respect to our assessment of the Agreement with AKP (Note 2 and 8), we identified three performance obligations under the agreement (Note 8), (i) the grant of a right to use of Apraglutide intellectual property license in Japan, (ii) to conduct development services, and (iii) to provide manufacturing and supply of Apraglutide for commercial purposes. Non-refundable up-front We estimate the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. We recognize revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. We allocate transaction price by estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain. Accordingly, we will recognize revenue for the grant of a right to use of Apraglutide intellectual property license in Japan at a point in time, as it relates to the upfront payment, when the right is granted. The regulatory milestones, sales milestones and royalties are all contingent on commercial sales of Apraglutide, and therefore, will be recognized based on the exception for sales and usage-based royalties received in exchange for licenses of intellectual property. As it relates to the development milestone payments, these will be recognized when the payments are considered certain or highly probable, since they are considered variable consideration. This will be reassessed at each reporting period and incremental payments in the form of additional milestones would be recognized if considered certain or highly probable. In relation to the performance obligation to conduct development services, revenue would be recognized over time, considering that the research and development services are satisfied over time. The customer has access to the activities over time as development occurs, therefore, we will recognize revenue based on the costs incurred as this method depicts the transfer of services. As it relates to the performance obligation of manufacturing and supply of Apraglutide for commercial purposes revenue will be recognized at a point in time when the transfer of control happens. Financial liabilities and derivatives Financial liabilities containing embedded derivatives On March 26, 2022, the Company entered into a Loan with Kreos (Note 2 and 18) structured to provide the EUR equivalent of up to USD 75.0 million in borrowing capacity and comprising two loan facilities of which EUR equivalent of USD 18.75 million is to be a convertible loan line and the remainder of the MLL, being a term loan of EUR equivalent of USD 56.25 million. Both loans contain various embedded derivatives related with extension clauses and early repayment clauses. In addition, the convertible loan contains an embedded derivative related to the conversion option. The Company has elected to designate both financial liabilities at fair value through profit and loss. As of June 30, 2022, no amounts have been drawn down from these loans. Refer to Note 2 and 18 for further information on these loans. Warrants In connection with the term loan and convertible loan agreements with Kreos, the Company issued warrants to Kreos to purchase 324,190 ordinary shares of the Company at a determined subscription price. The warrants are considered derivatives because there is no initial investment required, their value will vary based on future foreign currency exchange rates applied to a fixed USD price per share for the Company’s shares, and they will be settled in the future (seven years from the issue date). Although issued in connection with the Loan, the warrants have been considered standalone derivative, as described above because they are contractually transferable independently of the loans. They do not meet the criteria required for equity classification because their price is fixed in a foreign currency. Therefore, they will be recognized initially at fair value, classified as a financial liability, and measured at each reporting date at fair value with changes through profit and loss. Refer to Note 2 and 18 for further information on the warrants.

Critical accounting judgments

Critical accounting judgments	6 Months Ended
	Jun. 30, 2022
Significant Accounting Estimates And Judgments [Abstract]
Critical accounting judgments	5. Critical accounting judgments Going concern The Group has a limited operating history and has experienced net losses and significant cash used in operating activities since the inception of the Group. For the six-months The board of directors of the Company is of the opinion that, the cash position as of June 30, 2022 of USD 142,144 thousand (December 31, 2021: USD 102,707 thousand) is sufficient to continue operating through the next 12 months from this date and meet the Group’s ongoing operating requirements, recurring expenses and required capital expenditures as they arise. In addition, the Company has borrowing capacity from Kreos Loan tranches A1 and A2 of EUR equivalent of up to USD 50 million and tranche B of EUR equivalent of up to USD 25 million subject to certain conditions. Refer to Note 2 and 18 for further information.

Use of estimates in financial s

Use of estimates in financial statement presentation	6 Months Ended
	Jun. 30, 2022
Disclosure Of Use Of Estimates In Financial Statement Presentation [Abstract]
Use of estimates in financial statement presentation	6. Use of estimates in financial statement presentation The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of assets and liabilities, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions. Net pension liabilities The retirement benefit obligation is calculated based on various financial and actuarial assumptions. The key assumptions for assessing these obligations are the discount rate, interest credit rate, mortality rate, future salary and pension increases, average retirement age and expected life expectation at regular retirement age. The calculations of the defined benefit obligations are performed by external actuaries and the principal assumptions used are summarized in Note 17. As of June 30, 2022, the underfunding amounted to USD 2,436 thousand (December 31, 2021: USD 3,190 thousand). Refer to Note 17 for further information. Share-based payments The 2021 Equity Incentive Plan, 2020 Equity Incentive Plan, the 2020 RSPA, the 2019 Equity Incentive Plan and the 2019 RSPA instruments described in our annual consolidated and carve-out Valuation of warrant derivative Since the fair values of warrant derivatives recorded in the statement of financial position cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including a variation of the Black-Scholes option pricing model (Black model). The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions relating to these factors could affect the reported fair value of financial instruments. Refer to Note 18 for further information. Revenue from contracts with customers The Group has applied the following judgements that significantly affect the determination of the performance obligations under the contract with AKP: A good or service that is promised to a customer is distinct if both of the following criteria are met: (a) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer; and (b) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. The Group determined that the performance obligations identified - (i) the grant of a right to use of Apraglutide intellectual property license in Japan, (ii) to conduct development services, and (iii) to provide manufacturing and supply of Apraglutide for commercial purposes - are each capable of being distinct. In assessing whether each item has standalone value to the customer, the Group considers factors such as the development, manufacturing, and commercialization capabilities of the partner and the availability of the associated expertise in the general marketplace, which indicates that the customer can benefit from each of the license, the development services, and the manufacturing and supply of Apraglutide on their own. The Group also determined that the promises to transfer the license, to provide development services, and to manufacture and supply Apraglutide are distinct within the context of the contract. The license is separately identifiable in the contract and will be granted at contract inception. The license is not an input that will be integrated with the development services or manufacturing and supply of Apraglutide. The preparation and attendance of the various steering committees is to assist in conducting clinical trials and obtaining regulatory approval of the technology but does not modify the technology itself. In addition, the license, development services, and manufacturing and supply of Apraglutide are not highly interdependent or highly interrelated, because the delivery of license is not dependent on the services or deliveries of Apraglutide to be provided in the future, and accordingly, these promises are not interdependent or interrelated with each other. In determining whether the license transfers to a customer either at a point in time or over time, the Group considers whether the nature of the Group’s promise in granting the license to a customer is to provide a right to access or a right to use the Group’s intellectual property. The Group assessed that it provides a right to use the license as the license exists (in terms of form and functionality) at a point in time at which it is granted. The Group has allocated the transaction price to each performance obligation based on relative standalone selling prices.

Segment information

Segment information	6 Months Ended
	Jun. 30, 2022
Disclosure Of The Entity's Operating Segments [Abstract]
Segment information	7. Segment information The Group’s non-current

Revenue from contracts with cus

Revenue from contracts with customers	6 Months Ended
	Jun. 30, 2022
Receivables from contracts with customers [abstract]
Revenue from contracts with customers	8. Revenue from contracts with customers On March 30, 2022, the Company entered into the Agreement with AKP. Under the Agreement, the Company has granted an exclusive license to AKP, with the right to sublicense in multiple tiers, to develop, conduct medical affairs, conduct non-clinical, The Agreement will terminate at the later of: (a) the earlier of: (i) the date on which the product (including, the use, sale, offer for sale, importation, development, manufacturing or commercialization thereof) is no longer covered by any Group patent in Japan, and (ii) the date upon which a generic or biosimilar product is made available for commercial purchase in Japan; and (b) the date on which the last regulatory exclusivity for the product expires in Japan. Pursuant to the terms of the Agreement, the Company received an upfront payment of JPY 3,000 million (USD 24.61 million at date of agreement) and a payment of JPY 600 million related to development activities (USD 4.92 million at date of agreement). The Company is further eligible to receive payments of JPY 1,000 million related to development activities (USD 8.20 million at date of agreement) and to receive up to a possible total of JPY 20,000 million (USD 164.06 million at date of agreement) for various milestones as shown below: • Development milestones - JPY 1,000 million (USD 8.20 million at date of agreement); • Regulatory milestones - JPY 3,000 million (USD 24.61 million at date of agreement); and • Commercialization milestones - JPY 16,000 million (USD 131.25 million at date of agreement). The Company will also receive a cost-plus manufacturing mark-up mid-double-digit With respect to our assessment of the Agreement with AKP (Note 2 and 4), we identified three performance obligations under the agreement, (i) the grant of a right to use of Apraglutide intellectual property license in Japan, (ii) to conduct development services, and (iii) to provide manufacturing and supply of Apraglutide products for commercial purposes. The transaction price for the performance obligations related to the grant of intellectual property license in Japan and conducting development services has been determined to be JPY 23,000 million (USD 188.67 million at date of agreement) and JPY 1,600 million (USD 13.13 million at date of agreement), respectively, of which JPY 4,600 million (USD 37.74 million at date of agreement) are certain or highly probable, representing the upfront payment of JPY 3,000 million (USD 24.61 million at date of agreement) and the payments of JPY 1,600 million related to development activities (USD 13.13 million at date of agreement). We recognized an amount of revenue for the right to use of Apraglutide intellectual property license in Japan of USD 24.61 million and for conducting development services of USD 1.27 million for the six-months

Research and development expens

Research and development expenses	6 Months Ended
	Jun. 30, 2022
Research And Development Expense [Abstract]
Research and development expenses	9. Research and development expenses For the six-months ended June 30, In thousands of USD 2022 2021 Employee expenses (8,233 ) (6,177 ) Services expenses (i) (17,826 ) (15,838 ) Material expenses (i) (7,906 ) (2,237 ) License and IP expenses (ii) (79 ) (146 ) Consulting expenses (iii) (3,394 ) (1,143 ) Change in contingent consideration liabilities — (860 ) Depreciation and amortization expenses (73 ) (93 ) Total (37,511 ) (26,494 ) (i) Services and material expenses include services from third parties. (ii) License and intellectual property (“IP”) expenses mainly include legal cost in relation to IP. (iii) Consulting expenses include services of the scientific advisory and consultants who are not directly employed by the Group.

General and administrative expe

General and administrative expenses	6 Months Ended
	Jun. 30, 2022
Selling, general and administrative expense [abstract]
General and administrative expenses	10. General and administrative expenses For the six-months ended June 30, In thousands of USD 2022 2021 Employee expenses (9,318 ) (11,654 ) Professional services expenses (i) (7,956 ) (4,615 ) Travel and meeting expenses (304 ) (17 ) Facility expenses (31 ) (14 ) Insurance and other charges expenses (27 ) (1 ) Employee recruitment expenses (160 ) (1,071 ) IT maintenance and support expenses (835 ) (448 ) Capital tax and other non-income (78 ) (826 ) Depreciation and amortization expenses (48 ) (58 ) Office and other administrative expenses (533 ) (393 ) Total (19,290 ) (19,097 ) (i) Professional services expenses mainly include legal, accounting and other consulting expenses.

Financial income and expense

Financial income and expense	6 Months Ended
	Jun. 30, 2022
Financial Income And Expense [Abstract]
Financial income and expense	11. Financial income and expense For the six-months ended June 30, In thousands of USD 2022 2021 Interest income 18 — Financial income 18 — Interest expense on lease liabilities (1 ) (1 ) Kreos Loan facility fee expense (Note 18) (556 ) — Other interest expenses and bank charges (61 ) (22 ) Changes in fair value of warrant liabilities (4 ) — Financial expense (622 ) (23 ) Foreign exchange differences, net 1,126 496

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2022
Income Taxes [Abstract]
Income Taxes	12. Income taxes Income tax expense is recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year.

Share-based payments

Share-based payments	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangements [Abstract]
Share-based payments	13. Share-based payments The Company offered to certain directors, executive officers, employees, and external consultants, providing services similar to those rendered by employees, to participate in one of the three different share-based payment plans to receive restricted shares, share options, or RSUs. A total expense of USD 9,412 thousand for all share-based payment plans was recognized during the six-months 13.1 Restricted shares No restricted shares were granted during the six-months 13.2 Share options For the six-months The assessed fair value at grant date of share options granted is determined using an adjusted form of the Black-Scholes model that takes into account the exercise price and expected price volatility of the underlying share. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the share option is indicative of future trends, which may not necessarily be the actual outcome. The following tables list the inputs to the model used for the plans. The weighted-average assumptions used in estimating the fair value of share options with service conditions granted in 2022 and 2021 were as follows: As of June 30, 2022 As of June 30, 2021 Fair value per share 3.89 12.38 Exercise price 5.52 4.70 Volatility 64.65 % 58.10 % Duration 10 years 10 years A summary of share option activity, is presented below. June 30, 2022 Average exercise price (USD) per share option Number of Options Outstanding as of January 1, 2022 3.32 3,847,800 Granted during the period 5.52 2,154,900 Forfeited during the period 5.39 (191,441 ) Outstanding as of June 30, 2022 4.07 5,811,259 Vested as of June 30, 2022 3.57 1,219,631 Exercisable as of June 30, 2022 3.57 1,219,631 June 30, 2021 Average exercise price (USD) per share option Number of Outstanding as of January 1, 2021 0.05 1,252,900 Granted during the period 4.70 2,358,400 Forfeited during the period 0.05 (3,500 ) Outstanding as of June 30, 2021 3.09 3,607,800 Vested as of June 30, 2021 2.91 182,677 Exercisable as of June 30, 2021 2.91 182,677 Share options outstanding at the end of the period have the following expiry dates and exercise prices: Grant date Expiry date Exercise price Share options at August 31, 2019 August 31, 2029 0.05 46,000 October 1, 2019 October 1, 2029 0.05 10,000 February 29, 2020 February 29, 2030 0.05 6,000 September 30, 2020 September 30, 2030 0.05 1,187,400 January 31, 2021 January 31, 2031 0.05 5,000 February 28, 2021 February 28, 2031 0.05 40,000 March 31, 2021 March 31, 2031 0.05 60,000 April 30, 2021 April 30, 2031 4.80 1,726,176 May 31, 2021 May 31, 2031 4.80 428,600 June 30, 2021 June 30, 2031 11.66 40,000 September 30, 2021 September 30, 2031 7.73 160,000 September 30, 2021 September 30, 2031 4.80 40,000 December 31, 2021 December 31, 2031 4.91 40,000 January 31, 2022 January 31, 2032 4.83 130,000 February 28, 2022 February 28, 2032 5.65 1,610,483 March 31, 2022 March 31, 2032 4.71 15,000 April 30, 2022 April 30, 2032 4.50 110,000 May 31, 2022 May 31,2032 5.84 10,000 June 30, 2022 June 30,2032 5.40 146,600 Total 5,881,259 Weighted average fair value of options granted during the period (in USD) 3.89 Weighted average remaining contractual life of options outstanding at end of period (in years) 9.03 13.3 Restricted share units For the six-months June 30, 2022 Restricted share Weighted- average grant-date fair value Outstanding as of January 1, 2022 548,969 11.86 Granted during the period — — Vested (141,212 ) 12.45 Forfeited during the period (30,000 ) 15.55 Non-vested 377,757 11.35 June 30, 2021 Restricted share Weighted- average grant-date fair value Outstanding as of January 1, 2021 234,500 4.60 Granted during the period 446,000 15.55 Vested (25,761 ) 5.18 Forfeited during the period — — Non-vested 654.739 12.04 The RSUs include a net settlement feature under which the Company withholds shares in order to settle the employee’s s tax obligations. The Company equity-settles the RSUs on a net basis by withholding the number of shares with a fair value equal to the monetary value of the employee’s tax obligation and only issuing the remaining shares on completion of the vesting period. For the six-months

Loss per share

Loss per share	6 Months Ended
	Jun. 30, 2022
Earnings per share [abstract]
Loss per share	14. Loss per share The following summarizes basic and diluted loss per share for the period: In thousands of USD, except per share data For the six-months ended June 30, 2022 2021 Net loss attributable to ordinary shareholders (30,426 ) (45,118 ) Weighted average number of ordinary shares issued and outstanding 35,555,929 19,977,608 Basic and diluted loss per share (in USD) (0.86 ) (2.26 ) For the six-months non-vested Contingently issuable shares per terms of the anti-dilution protection granted to the Company’s issued warrants, were not evaluated for their dilutive effect, as the conditions for their conversion were not met as of June 30, 2022, and thus, were not included in diluted earnings per share. six-months non-vested non-vested non-vested

Goodwill and intangible assets

Goodwill and intangible assets	6 Months Ended
	Jun. 30, 2022
Intangible assets and goodwill [abstract]
Goodwill and intangible assets	15. Goodwill and intangible assets Goodwill and intangible assets In thousands of USD Goodwill Apraglutide Comet Platform Total COST Balance as of January 1, 2022 925 22,334 2,788 26,047 Additions — — — — Retirements — — — — Foreign exchange difference (31 ) (751 ) — (782 ) Balance as of June 30, 2022 894 21,583 2,788 25,265 As of June 30, 2022, there were no indicators of impairment of any of the CGUs.

Share capital

Share capital	6 Months Ended
	Jun. 30, 2022
Share Capital [Abstract]
Share capital	16. Share capital June 30, 2022 Number of Nominal value of Ordinary shares (in thousands of Balance as of January 1, 2022 36,635,713 1,935 Issuance of ordinary shares 14,056,077 726 Balance as of June 30, 2022 50,691,790 2,661 June 30, 2021 Number of Nominal value Ordinary shares (in thousands of Balance as of January 1, 2021 13,042,080 1,409 Issuance of ordinary shares 22,819,788 486 Balance as of June 30, 2021 35,861,868 1,895 16.1 Issued share capital As of June 30, 2022, the issued share capital amounted to CHF 2,534,589.50 (USD 2,661 thousand) (December 31, 2021: CHF 1,831,785.65 (USD 1,935 thousand)), consisting of 46,037,642 issued and outstanding ordinary shares with a nominal value of CHF 0.05 (USD 0.05) per share (December 31, 2021: 35,973,339 issued and outstanding ordinary shares) and 4,654,148 ordinary shares held in treasury (December 31, 2021: 662,374 ordinary shares) (Note 16.2). Except for the treasury shares, all of these shares have the same voting rights. Since January 1, 2022, the issued share capital increased as follows: On May 6, 2022, the Company issued 3,053,008 ordinary shares with a nominal value of CHF 0.05 per share from authorized share capital to be held in treasury for purposes of one or several placements with investors or acquisitions. On June 17, 2022, the Company issued from authorized share capital and sold 5,715,000 ordinary shares with a nominal value of CHF 0.05 per share to the underwriters. On June 23, 2022, the Company issued from authorized share capital and sold additional 752,688 ordinary shares with a nominal value of CHF 0.05 per share to the underwriters pursuant to the partial exercise of the underwriters’ previously granted option to purchase additional ordinary shares. The aggregate gross proceeds of the public offering amounted to USD 34 million, before deducting underwriting discounts and commissions and other offering expenses. Also, during June 2022, Forbion purchased an aggregate of 3,478,260 ordinary shares with a nominal value of CHF 0.05 per share at a price of USD 5.75 per share, for gross proceeds of USD 20 million, in a private placement. The 3,478,260 ordinary shares consisted of 425,252 ordinary shares issued from authorized share capital on June 23, 2022 and 3,053,008 treasury shares sold to Forbion on June 27, 2022. On June 30, 2022, the board of directors of the Company resolved to issue 4,110,129 ordinary shares with a nominal value of CHF 0.05 per share from authorized share capital to be held in treasury for purposes of one or several placements with investors or acquisitions. The capital increase was entered in the commercial register on July 4, 2022. As a result of these transactions, the Company has incurred transaction costs amounting to a total of USD 4,496 thousand during the period until June 30, 2022. The transaction costs arising from recent share issuances as well as those incurred in previous periods have been accounted for as a reduction of equity, net of any related income tax benefit. 16.2 Treasury shares Treasury shares are shares of the Company that are held by the Group mainly for the purpose of issuing shares under the Group’s equity-settled share-based payment plans for its employees and placements with investors or acquisitions. For the six-months 162 44 six-months June 30, 2022 Number of (in thousands of Balance as of January 1, 2022 (662,374 ) (35 ) Shares allocated for RSUs net settlement (Note 13) 118,355 (331 ) Shares issued (4,110,129 ) (215 ) Balance as of June 30, 2022 (4,654,148 ) (581 ) 16.3 Authorized share capital As of June 30, 2022, the authorized share capital amounted to CHF 90,896.15 (USD 95 thousand) (December 31, 2021: CHF 793,700 (USD 860 thousand)), consisting of 1,817,923 ordinary shares (December 31, 2021: 15,874,000 ordinary shares), with a nominal value of CHF 0.05 (USD 0.05) per share. On June 30, 2022, the annual general meeting of shareholders of the Company resolved the increase and renewal of the authorized share capital to CHF 992,218.00 (USD 1,038 thousand), consisting of 19,844,360 ordinary shares with a nominal value of CHF 0.05 (USD 0.05) per share until June 30, 2024. The resolutions of the annual general meeting of shareholders were entered in the commercial register on July 4, 2022. 16.4 Conditional share capital As of June 30, 2022, the conditional share capital amounted to CHF 832,392.25 (USD 871 thousand) (December 31, 2021: CHF 832,392.25 (USD 973 thousand)), consisting of 16,647,845 ordinary shares (December 31, 2021: 16,647,845 ordinary shares) with a nominal value of CHF 0.05 (USD 0.05) per share. On June 30, 2022, the annual general meeting of shareholders of the Company resolved to increase the conditional share capital for participation programs to CHF 541,332.00 (USD 567 thousand), consisting of 10,826,640 ordinary shares with a nominal value of CHF 0.05 (USD 0.05) per share. The resolution of the annual general meeting of shareholders was entered in the commercial register on July 4, 2022, resulting in an aggregate conditional share capital of CHF 992,218.00 (USD 1,038 thousand), consisting of 19,844,360 ordinary shares with a nominal value of CHF 0.05 (USD 0.05) per share.

Defined benefit plan

Defined benefit plan	6 Months Ended
	Jun. 30, 2022
Disclosure of defined benefit plans [abstract]
Defined benefit plan	17. Defined benefit plan No curtailment or settlement occurred during the six-months The most recent actuarial valuations of plan assets and the present value of the defined benefit obligation were carried out as of June 30, 2022, by an independent third party. The present value of the defined benefit obligation, and the related current service cost and past service cost, were measured using the Projected Unit Credit method. The amounts recognized through profit or loss as employee benefits expense either within research and development expenses or within general and administrative expenses, depending on their function with respect to the defined benefit plans, are as follows: For the six-months ended June 30, In thousands of USD 2022 2021 Current service cost 718 370 Interest cost 22 8 Expected return on plan assets (18 ) (7 ) Administration costs 2 3 Expense recognized in profit or loss 724 374 The amounts recognized in other comprehensive loss with respect to the defined benefit plans are as follows: For the six-months ended June 30, In thousands of USD 2022 2021 Remeasurement (gain)/loss on defined benefit obligation Actuarial (gains)/losses arising from plan experience 1,215 264 Actuarial (gains)/losses arising from demographic assumption — (570 ) Actuarial (gains)/losses arising from financial assumptions (3,213 ) (310 ) Return on plan assets excl. interest income 1,168 108 Expense recognized in other comprehensive loss (830 ) (508 ) The amount included in the unaudited interim condensed consolidated statements of financial position arising from the Group’s obligation in respect to its defined benefit plan is as follows: In thousands of USD For the six- months ended Present value of defined benefit obligation 14,424 Fair value of plan assets (11,988 ) Net liability arising from defined benefit obligation 2,436 Movements in the present value of the defined benefit obligation in the reporting period were as follows: In thousands of USD 2022 Beginning defined benefit obligation as of January 1 14,936 Current service cost 718 Interest expense on defined benefit obligation 22 Contributions paid by employees 432 Benefits (paid)/deposited 1,041 Remeasurement (gain)/loss on defined benefit obligation (1,998 ) Other 5 Foreign currency exchange (gains)/losses (732 ) Ending defined benefit obligation as of June 30 14,424 Movements in the present value of the plan assets in the reporting period were as follows: In thousands of USD 2022 Beginning fair value of plan assets as of January 1 11,710 Return on plan assets excluding interest income 18 Contributions paid by employer 549 Contributions paid by employees 436 Benefits (paid)/deposited 1,041 Actuarial gain/(loss) on plan assets (1,168 ) Administration expense (2 ) Other (5 ) Foreign currency exchange gains/(losses) (591 ) Ending fair value of plan assets as of June 30 11,988 The allocation of the assets of the different asset classes corresponds to: June 30, 2022 Cash 1.0 % Bonds 60.1 % Equities 25.7 % Properties 10.1 % Other 3.1 % Total 100.0 % Principal assumptions used for the purposes of the actuarial valuations were as follows: June 30, 2022 Discount rate 2.0 % Interest credit rate 2.0 % Expected rate of salary increase 2.0 % Expected rate of pension increase 0.0 % Mortality rate BVG 2020 GT The following sensitivity analyses - based on the principal assumptions - have been performed based on reasonably possible changes to the assumptions occurring at the end of the reporting period: If the discount rate would increase/(decrease) by 25 basis points, the defined benefit obligation would decrease by USD 283 thousand (increase by USD 298 thousand) if all other assumptions were held constant. If the expected salary growth would increase (decrease) by 25 basis points, the defined benefit obligation would increase by USD 59 thousand (decrease by USD 59 thousand) if all other assumptions were held constant. If the expected pension growth would increase by 25 basis points, the defined benefit obligation would increase by USD 230 thousand if all other assumptions were held constant. No sensitivity analysis was performed on other assumptions as a similar change to those assumptions would not have a significant impact on these unaudited interim condensed consolidated financial statements. The average duration of the defined benefit obligation at the end of the reporting period is 15 years. The Group expects to make contributions of USD 370 thousand to the defined benefit plan during the second half of 2022.

Financial Liabilities and Deriv

Financial Liabilities and Derivatives	6 Months Ended
	Jun. 30, 2022
Financial Liabilities and Derivatives [Abstract]
Financial Liabilities and Derivatives	18. Financial liabilities and derivatives On March 26, 2022, the Company entered into a note financing agreement (the “Loan”) with Kreos Capital VI (UK) Limited (“Kreos”). The debt facility is structured to provide the EUR equivalent of up to USD 75.0 million in borrowing capacity under a master loan line. The master loan line is comprised of two loan facilities, of which the EUR equivalent of USD 18.75 million is a convertible loan line, (the “Convertible Loan”) and the EUR equivalent of USD 56.25 million is a term loan line (the “Term Loan”), each of which may be drawn down in three tranches as follows: Loan A1: Convertible Loan – EUR equivalent of USD 7.5 million Term Loan – EUR equivalent of USD 22.5 million Loan A2: Convertible Loan – EUR equivalent of USD 5.0 million Term Loan – EUR equivalent of USD 15.0 million Loan B: Convertible Loan – EUR equivalent of USD 6.25 million Term Loan – EUR equivalent of USD 18.75 million The tranches of the Convertible Loan and the Term Loan under Loan A1 and Loan A2 are available for drawdown until September 30, 2022. The Company is obligated to draw down the first portion of Loan A1 and Loan A2 in an amount of at least the EUR equivalent of USD 10.0 million by September 30, 2022, with the EUR equivalent of USD 2.5 million comprising the Convertible Loan portion (the “Minimum Convertible Note”). The tranches of the Convertible Loan and the Term Loan under Loan B will be available for drawdown until December 31, 2022, subject to certain conditions. The availability of any funds under a drawdown of Loan A1, Loan A2 or Loan B is conditional upon the Group having a debt-to-market The availability of any funds under a drawdown of Loan B is conditional upon the Group (i) raising USD 80 million in new equity and/or subordinated convertible debt, or other non-dilutive The Convertible Loan and the Term Loan have an interest-only repayment period until March 31, 2023, which can be extended in two extensions to June 30, 2024, at the latest, if certain conditions are met. Payments will then be comprised of both interest and principal until both loans are paid off, with an end date ranging from March 31, 2025 to June 30, 2026, if the interest-only period has been extended to June 30, 2024. In connection with both the Convertible Loan and the Term Loan, the Company and each of its subsidiaries have entered into pledge agreements in respect of the Group’s worldwide intellectual property in favor of Kreos as pledgee (excluding intellectual property in respect of Apraglutide granted, issued, or pending in Japan). VectivBio Holding AG, VectivBio AG and VectivBio Comet AG additionally entered into pledge agreements pledging (i) all of the share capital of VectivBio AG and VectivBio Comet AG, and (ii) all of the Swiss bank accounts of VectivBio Holding AG, VectivBio AG and VectivBio Comet AG, in each case, in favor of Kreos. VectivBio Holding AG, VectivBio AG and VectivBio Comet AG additionally entered into an agreement guaranteeing Kreos’s claims under both the Convertible Loan and the Term Loan. VectivBio AG also assigned to Kreos certain rights under licensing agreements for security purposes. Under the abovementioned security agreements, Kreos will have recourse to the relevant collateral in the event the Company defaults under the Convertible Loan and the Term Loan. The Convertible Loan and the Term Loan contain customary affirmative and negative covenants. The affirmative covenants include, among others, administrative and reporting requirements subject to certain exceptions and materiality thresholds. The negative covenants include, among others, limitations on the Company’s ability to, subject to certain exceptions, incur additional debt. The Company may prepay all, but not part, of the Term Loan and the Convertible Loan amounts at any time, by notifying the lender at least fifteen days in advance of the first business day of each month; provided, however, that Kreos may at its option convert amounts outstanding under the Convertible Loan into ordinary shares after receipt of any such prepayment notification. In connection with this agreement, the Company has paid an amount of USD 750 thousand for transactions fees. Since the Company does not expect to utilize the facility with exception to the amount of compulsory drawdown, the amount of transaction fees has been apportioned between the amount expected to be utilized, and the amount not expected to be utilized. The portion related to the compulsory drawdown is deferred until such drawdown, when it will be recognized as an expense, since the respective amount of loan will be measured at fair value through profit and loss. The remaining portion represents a payment for liquidity services, and thus, is initially capitalized and subsequently expensed over the facility period on a straight-line basis. In the six-months six-months Convertible Loan As of June 30, 2022, no amount has been drawn down in connection with the Convertible Loan, therefore no amount has been recorded in the unaudited interim condensed consolidated financial statements. Borrowing under the Convertible Loan bear interest at an implied fixed rate of 7.45% per annum. The Minimum Convertible Note will be convertible upon draw down into 356,961 ordinary shares at a price per ordinary share of USD 7.0036. The remaining Convertible Loan amount is convertible upon subsequent drawdowns, if any, into a number of ordinary shares to be determined based on a price per ordinary share that is at a 130% premium to the volume weighted average price of shares traded during the 30-day Based on the term and conditions of the Convertible Loan, the Group has concluded that the Convertible Loan includes a financial liability and a written embedded conversion option from the perspective of the issuer, since it is denominated in a currency other than the functional currency of the Company, thus failing the requirement of exchanging a fixed amount of cash or another financial asset for a fixed number of equity instruments to qualify as an equity instrument. The embedded written option has not been determined to be a closely related embedded derivative and therefore susceptible to be separated and measured at fair value through profit or loss. In addition, the Convertible Loan contains additional embedded derivatives related with extension clauses and early repayment clauses: • Extension clauses: a first extension option to December 31, 2025 subject to: (i) raising USD 80 million in new equity and/or subordinated convertible debt from existing or new investors, and/or licensing milestone payments or other payments made under a licensing agreement; and (ii) release of interim data for the Phase 2 STARS Nutrition study which supports continuation of such study; a second extension option to June 30, 2026 subject to announcement of positive Phase 3 results for the SBS-IF • Early repayment clauses: the Convertible Loan has several early repayment options which vary depending on the period when the loan is repaid (ranging from within 12 months up to after 37 months since drawdown) and have different conditions based on such periods or early repayment (ranging from principal outstanding, plus future interest to final repayment date discounted at 4% per annum to 101% of principal outstanding, in any case plus costs and additional payments of 3% of the amount drawn down not payable on amounts converted). Pursuant to all terms and conditions described above, the instrument meets the definition of a hybrid instrument under IFRS 9. However, the Group has elected the fair value option, whereby the Convertible Loan, including all the embedded derivatives, will be accounted for as one instrument (not separating the loan from the derivatives) at fair value with changes in fair value for each reporting period recorded in profit or loss. Term Loan As of June 30, 2022, no amount has been drawn down in connection with the Term Loan, therefore no amount has been recorded in these unaudited interim condensed consolidated financial statements. Borrowings under the Term Loan bear interest at an implied fixed rate of 8.95% per annum. The Term Loan contains the same clauses described above for the Convertible Loan related to extension of the term of the loan and early repayment of the loan. Such clauses have been considered derivatives embedded in the Term Loan. Therefore, the instrument meets the definition of a hybrid instrument under IFRS 9. However, the Group has elected the fair value option also for the Term Loan. As a consequence, the Term Loan, including the embedded derivatives, will be accounted for as one instrument (not separating the loan from the derivatives) at fair value with changes in fair value for each reporting period recorded in profit or loss. Warrants On March 26, 2022, in connection with the agreement with Kreos described above, the Company also granted warrants to Kreos to purchase 324,190 ordinary shares of the Company issuable upon the exercise of the warrant at an exercise price of USD 5.5243 per share, recognizing the fair value amounting USD 1,120 thousand in the line-item of Other current assets and Warrant liability, respectively. As with the transaction fee, since the Company does not expect to utilize the facility with exception to the amount of compulsory drawdown, the initial fair value of the warrants has been apportioned between the amount expected to be utilized, and the amount not expected to be utilized. The portion related to the compulsory drawdown is deferred until such drawdown. The remaining portion represents a payment for liquidity services, and thus, is expensed over the facility period on a straight-line basis. In the six-months The Company will grant to Kreos additional warrants to purchase ordinary shares with an aggregate value of up to a maximum of USD 1.0 million, with an exercise price per share equal to the volume weighted average price per share for the 30-day The warrants are exercisable for a period of seven years from the date of issuance. As described in Note 4, the warrants have been considered as standalone derivatives and measured at fair value with changes through profit and loss. The fair value of the warrants as of June 30, 2022, amounts to USD 1,124 thousand and the changes in fair value recorded in the six-months The following assumptions were used to calculate the fair value of the warrants: Assumptions June 30, 2022 Expected volatility 64.8 % Expected term (in years) 6.7 Risk-free interest rate 2.3 % Dividiend yield 0.0 %

Financial instruments

Financial instruments	6 Months Ended
	Jun. 30, 2022
Financial Instrments [Abstract]
Financial instruments	19. Financial instruments 19.1 Capital management The Group’s objectives when managing capital are to safeguard its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. 19.2 Categories of financial instruments As of June 30, 2022 In thousands of USD Financial assets and cash Financial Financial Total Financial assets 59 — — 59 Cash and cash equivalents 142,144 — — 142,144 Total financial assets 142,203 — — 142,203 Warrant liability — 1,124 — 1,124 Lease liabilities — — 221 221 Trade payables — — 12,527 12,527 Accrued expenses — — 14,944 14,944 Other current liabilities — — 1,445 1,445 Total financial liabilities — 1,124 29,137 30,261 As of December 31, 2021 In thousands of USD Financial assets and cash Financial Financial Total Financial assets 61 — — 61 Other current assets 4 — — 4 Cash and cash equivalents 102,707 — — 102,707 Total financial assets 102,772 — — 102,772 Lease liabilities — — 292 292 Trade payables — — 8,595 8,595 Accrued expenses — — 8,339 8,339 Total financial liabilities — — 17,226 17,226 The carrying amounts of financial assets and financial liabilities recognized in the unaudited interim condensed consolidated financial statements approximate their fair values.

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2022
Related party transactions [abstract]
Related party transactions	20. Related party transactions 20.1 Compensation for Executive Management and Board of Directors (“BOD”) For the six-months ended June 30, In thousands of USD 2022 2021 Fees, salaries and other short-term employee benefits 2,519 1,912 Post-employment benefits 493 396 Share-based compensation 7,717 8,449 Total compensation for Executive Management and BOD 10,729 10,757 20.2 Related party balances and transactions As of June 30, 2022, and December 31, 2021, there were no

Contract Balances

Contract Balances	6 Months Ended
	Jun. 30, 2022
Contract liabilities [abstract]
Contract Liabilities [Text Block]	21. Contract balances Contract liabilities amounting USD 3,488 0

Events after reporting period

Events after reporting period	6 Months Ended
	Jun. 30, 2022
Disclosure of non-adjusting events after reporting period [abstract]
Events after the reporting period	22. Events after the reporting period On July 4, 2022, Comet Therapeutics, Inc. was merged into VectivBio Comet AG, taking over all assets and liabilities of Comet Therapeutics, Inc. at book value. The Intellectual Property right is the relevant asset of Comet Therapeutics, Inc. and the fair value of the IP amounts to USD 6.43 million (CHF 5.86 million). On October 12 • Loan A: Convertible Loan – EUR equivalent of USD 12.5 million; Term Loan – EUR equivalent of USD 37.5 million; and • Loan B: Convertible Loan – EUR equivalent of USD 6.25 million; Term Loan – EUR equivalent of USD 18.75 million. Loan A has been extended and will be available for drawdown until May 31, 2024. Loan B has been extended and will be available for drawdown until June 30, 2024. Contemporaneously with execution of the Amended Loan, we delivered to Kreos drawdown requests under Loan A for an aggregate amount equal to the EUR equivalent of USD 10 million. Under the Amended Loan, we must deliver to Kreos further drawdown requests under Loan A for an aggregate amount equal to the EUR equivalent of USD 10 million by September 30, 2023. The Amended Loan also contains certain repayment fees and granted Kreos the right to receive additional warrants on prepayment of borrowings. The financial effect of the Amended Loan on the Group is yet to be estimated.

Summary of selected significa_2

Summary of selected significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Significant Accounting Policies [Abstract]
New and amended Standards and Interpretations that are mandatorily effective for the current year	New and amended Standards and Interpretations that are mandatorily effective for the current year The following standards and interpretations apply for the first time to financial reporting periods commencing on or after January 1, 2022: Title Effective Date Amendments to IAS 16 – Property, Plant and Equipment: Proceeds before intended use January 1, 2022 Amendments to IFRS 3 – Reference to the Conceptual Framework January 1, 2022 Amendments to IAS 37 – Onerous Contracts – Cost of Fulfilling a Contract January 1, 2022 Annual Improvements to IFRS 9 Financial Instruments – clarifies which fees should be included in the 10% test for derecognition of financial liabilities. January 1, 2022 Annual Improvements to IFRS 16 Leases – amendment to remove any confusion about the treatment of lease incentives. January 1, 2022 The adoption of such standards did not have a significant impact on the unaudited interim condensed consolidated statements of financial position or statements of operations and other comprehensive loss of the Group. New accounting policies applied in the preparation of the unaudited interim condensed consolidated financial statements as of and for the six-months
Revenue recognition	Revenue recognition Our revenue is derived from contracts with customers in accordance with IFRS 15, mainly from the Agreement with AKP (Note 2 and 8). Based on IFRS 15, we have performed the following steps in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under this agreement: 1. Identification of the promised goods or services in the contract; 2. Determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; 3. Measurement of the transaction price, including the constraint on variable consideration; 4. Allocation of the transaction price to the performance obligations; and 5. Recognition of revenue when each performance obligation is satisfied. For the licensing agreement we have considered a variety of factors in determining the appropriate estimates and assumptions, such as whether the elements within the agreement are distinct performance obligations, whether there are observable standalone selling prices, and whether the customer has right to use or a right to access a license. We have evaluated each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. With respect to our assessment of the Agreement with AKP (Note 2 and 8), we identified three performance obligations under the agreement (Note 8), (i) the grant of a right to use of Apraglutide intellectual property license in Japan, (ii) to conduct development services, and (iii) to provide manufacturing and supply of Apraglutide for commercial purposes. Non-refundable up-front We estimate the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. We recognize revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. We allocate transaction price by estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain. Accordingly, we will recognize revenue for the grant of a right to use of Apraglutide intellectual property license in Japan at a point in time, as it relates to the upfront payment, when the right is granted. The regulatory milestones, sales milestones and royalties are all contingent on commercial sales of Apraglutide, and therefore, will be recognized based on the exception for sales and usage-based royalties received in exchange for licenses of intellectual property. As it relates to the development milestone payments, these will be recognized when the payments are considered certain or highly probable, since they are considered variable consideration. This will be reassessed at each reporting period and incremental payments in the form of additional milestones would be recognized if considered certain or highly probable. In relation to the performance obligation to conduct development services, revenue would be recognized over time, considering that the research and development services are satisfied over time. The customer has access to the activities over time as development occurs, therefore, we will recognize revenue based on the costs incurred as this method depicts the transfer of services. As it relates to the performance obligation of manufacturing and supply of Apraglutide for commercial purposes revenue will be recognized at a point in time when the transfer of control happens.
Financial liabilities and derivatives	Financial liabilities and derivatives Financial liabilities containing embedded derivatives On March 26, 2022, the Company entered into a Loan with Kreos (Note 2 and 18) structured to provide the EUR equivalent of up to USD 75.0 million in borrowing capacity and comprising two loan facilities of which EUR equivalent of USD 18.75 million is to be a convertible loan line and the remainder of the MLL, being a term loan of EUR equivalent of USD 56.25 million. Both loans contain various embedded derivatives related with extension clauses and early repayment clauses. In addition, the convertible loan contains an embedded derivative related to the conversion option. The Company has elected to designate both financial liabilities at fair value through profit and loss. As of June 30, 2022, no amounts have been drawn down from these loans. Refer to Note 2 and 18 for further information on these loans. Warrants In connection with the term loan and convertible loan agreements with Kreos, the Company issued warrants to Kreos to purchase 324,190 ordinary shares of the Company at a determined subscription price. The warrants are considered derivatives because there is no initial investment required, their value will vary based on future foreign currency exchange rates applied to a fixed USD price per share for the Company’s shares, and they will be settled in the future (seven years from the issue date). Although issued in connection with the Loan, the warrants have been considered standalone derivative, as described above because they are contractually transferable independently of the loans. They do not meet the criteria required for equity classification because their price is fixed in a foreign currency. Therefore, they will be recognized initially at fair value, classified as a financial liability, and measured at each reporting date at fair value with changes through profit and loss. Refer to Note 2 and 18 for further information on the warrants.

Summary of selected significa_3

Summary of selected significant accounting policies (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of initial application of standards or interpretations [line items]
Schedule of Initial Application of Standards or Interpretations	The following standards and interpretations apply for the first time to financial reporting periods commencing on or after January 1, 2022: Title Effective Date Amendments to IAS 16 – Property, Plant and Equipment: Proceeds before intended use January 1, 2022 Amendments to IFRS 3 – Reference to the Conceptual Framework January 1, 2022 Amendments to IAS 37 – Onerous Contracts – Cost of Fulfilling a Contract January 1, 2022 Annual Improvements to IFRS 9 Financial Instruments – clarifies which fees should be included in the 10% test for derecognition of financial liabilities. January 1, 2022 Annual Improvements to IFRS 16 Leases – amendment to remove any confusion about the treatment of lease incentives. January 1, 2022

Research and development expe_2

Research and development expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Research And Development Expense [Abstract]
Schedule of Research and Development Expense	For the six-months ended June 30, In thousands of USD 2022 2021 Employee expenses (8,233 ) (6,177 ) Services expenses (i) (17,826 ) (15,838 ) Material expenses (i) (7,906 ) (2,237 ) License and IP expenses (ii) (79 ) (146 ) Consulting expenses (iii) (3,394 ) (1,143 ) Change in contingent consideration liabilities — (860 ) Depreciation and amortization expenses (73 ) (93 ) Total (37,511 ) (26,494 ) (i) Services and material expenses include services from third parties. (ii) License and intellectual property (“IP”) expenses mainly include legal cost in relation to IP. (iii) Consulting expenses include services of the scientific advisory and consultants who are not directly employed by the Group.

General and administrative ex_2

General and administrative expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Selling, general and administrative expense [abstract]
Schedule of General and Administrative Expenses	For the six-months ended June 30, In thousands of USD 2022 2021 Employee expenses (9,318 ) (11,654 ) Professional services expenses (i) (7,956 ) (4,615 ) Travel and meeting expenses (304 ) (17 ) Facility expenses (31 ) (14 ) Insurance and other charges expenses (27 ) (1 ) Employee recruitment expenses (160 ) (1,071 ) IT maintenance and support expenses (835 ) (448 ) Capital tax and other non-income (78 ) (826 ) Depreciation and amortization expenses (48 ) (58 ) Office and other administrative expenses (533 ) (393 ) Total (19,290 ) (19,097 ) (i) Professional services expenses mainly include legal, accounting and other consulting expenses.

Financial income and expense (T

Financial income and expense (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Income And Expense [Abstract]
Schedule of Finance Income and Expense	For the six-months ended June 30, In thousands of USD 2022 2021 Interest income 18 — Financial income 18 — Interest expense on lease liabilities (1 ) (1 ) Kreos Loan facility fee expense (Note 18) (556 ) — Other interest expenses and bank charges (61 ) (22 ) Changes in fair value of warrant liabilities (4 ) — Financial expense (622 ) (23 ) Foreign exchange differences, net 1,126 496

Share-based payments (Tables)

Share-based payments (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangements [Abstract]
Fair Value Assumptions of Share Options Granted	The weighted-average assumptions used in estimating the fair value of share options with service conditions granted in 2022 and 2021 were as follows: As of June 30, 2022 As of June 30, 2021 Fair value per share 3.89 12.38 Exercise price 5.52 4.70 Volatility 64.65 % 58.10 % Duration 10 years 10 years
Share Option Activity	A summary of share option activity, is presented below. June 30, 2022 Average exercise price (USD) per share option Number of Options Outstanding as of January 1, 2022 3.32 3,847,800 Granted during the period 5.52 2,154,900 Forfeited during the period 5.39 (191,441 ) Outstanding as of June 30, 2022 4.07 5,811,259 Vested as of June 30, 2022 3.57 1,219,631 Exercisable as of June 30, 2022 3.57 1,219,631 June 30, 2021 Average exercise price (USD) per share option Number of Outstanding as of January 1, 2021 0.05 1,252,900 Granted during the period 4.70 2,358,400 Forfeited during the period 0.05 (3,500 ) Outstanding as of June 30, 2021 3.09 3,607,800 Vested as of June 30, 2021 2.91 182,677 Exercisable as of June 30, 2021 2.91 182,677 Share options outstanding at the end of the period have the following expiry dates and exercise prices: Grant date Expiry date Exercise price Share options at August 31, 2019 August 31, 2029 0.05 46,000 October 1, 2019 October 1, 2029 0.05 10,000 February 29, 2020 February 29, 2030 0.05 6,000 September 30, 2020 September 30, 2030 0.05 1,187,400 January 31, 2021 January 31, 2031 0.05 5,000 February 28, 2021 February 28, 2031 0.05 40,000 March 31, 2021 March 31, 2031 0.05 60,000 April 30, 2021 April 30, 2031 4.80 1,726,176 May 31, 2021 May 31, 2031 4.80 428,600 June 30, 2021 June 30, 2031 11.66 40,000 September 30, 2021 September 30, 2031 7.73 160,000 September 30, 2021 September 30, 2031 4.80 40,000 December 31, 2021 December 31, 2031 4.91 40,000 January 31, 2022 January 31, 2032 4.83 130,000 February 28, 2022 February 28, 2032 5.65 1,610,483 March 31, 2022 March 31, 2032 4.71 15,000 April 30, 2022 April 30, 2032 4.50 110,000 May 31, 2022 May 31,2032 5.84 10,000 June 30, 2022 June 30,2032 5.40 146,600 Total 5,881,259 Weighted average fair value of options granted during the period (in USD) 3.89 Weighted average remaining contractual life of options outstanding at end of period (in years) 9.03
Restricted Stock Unit Activity	June 30, 2022 Restricted share Weighted- average grant-date fair value Outstanding as of January 1, 2022 548,969 11.86 Granted during the period — — Vested (141,212 ) 12.45 Forfeited during the period (30,000 ) 15.55 Non-vested 377,757 11.35 June 30, 2021 Restricted share Weighted- average grant-date fair value Outstanding as of January 1, 2021 234,500 4.60 Granted during the period 446,000 15.55 Vested (25,761 ) 5.18 Forfeited during the period — — Non-vested 654.739 12.04

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings per share [abstract]
Schedule of Loss per Share	The following summarizes basic and diluted loss per share for the period: In thousands of USD, except per share data For the six-months ended June 30, 2022 2021 Net loss attributable to ordinary shareholders (30,426 ) (45,118 ) Weighted average number of ordinary shares issued and outstanding 35,555,929 19,977,608 Basic and diluted loss per share (in USD) (0.86 ) (2.26 )

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	6 Months Ended
	Jun. 30, 2022
Intangible assets and goodwill [abstract]
Schedule of Goodwill and Intangible Assets	Goodwill and intangible assets In thousands of USD Goodwill Apraglutide Comet Platform Total COST Balance as of January 1, 2022 925 22,334 2,788 26,047 Additions — — — — Retirements — — — — Foreign exchange difference (31 ) (751 ) — (782 ) Balance as of June 30, 2022 894 21,583 2,788 25,265

Share capital (Tables)

Share capital (Tables)	6 Months Ended
	Jun. 30, 2022
Share Capital [Abstract]
Classes of Share Capital	June 30, 2022 Number of Nominal value of Ordinary shares (in thousands of Balance as of January 1, 2022 36,635,713 1,935 Issuance of ordinary shares 14,056,077 726 Balance as of June 30, 2022 50,691,790 2,661 June 30, 2021 Number of Nominal value Ordinary shares (in thousands of Balance as of January 1, 2021 13,042,080 1,409 Issuance of ordinary shares 22,819,788 486 Balance as of June 30, 2021 35,861,868 1,895 six-months June 30, 2022 Number of (in thousands of Balance as of January 1, 2022 (662,374 ) (35 ) Shares allocated for RSUs net settlement (Note 13) 118,355 (331 ) Shares issued (4,110,129 ) (215 ) Balance as of June 30, 2022 (4,654,148 ) (581 )

Defined benefit plan (Tables)

Defined benefit plan (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of defined benefit plans [abstract]
Defined Benefit Plan, Expense Recognized in Profit or Loss	The amounts recognized through profit or loss as employee benefits expense either within research and development expenses or within general and administrative expenses, depending on their function with respect to the defined benefit plans, are as follows: For the six-months ended June 30, In thousands of USD 2022 2021 Current service cost 718 370 Interest cost 22 8 Expected return on plan assets (18 ) (7 ) Administration costs 2 3 Expense recognized in profit or loss 724 374
Defined Benefit Plan, Expense Recognized in Other Comprehensive Income	The amounts recognized in other comprehensive loss with respect to the defined benefit plans are as follows: For the six-months ended June 30, In thousands of USD 2022 2021 Remeasurement (gain)/loss on defined benefit obligation Actuarial (gains)/losses arising from plan experience 1,215 264 Actuarial (gains)/losses arising from demographic assumption — (570 ) Actuarial (gains)/losses arising from financial assumptions (3,213 ) (310 ) Return on plan assets excl. interest income 1,168 108 Expense recognized in other comprehensive loss (830 ) (508 )
Disclosure of Net Defined Benefit Liability Obligation	The amount included in the unaudited interim condensed consolidated statements of financial position arising from the Group’s obligation in respect to its defined benefit plan is as follows: In thousands of USD For the six- months ended Present value of defined benefit obligation 14,424 Fair value of plan assets (11,988 ) Net liability arising from defined benefit obligation 2,436 Movements in the present value of the defined benefit obligation in the reporting period were as follows: In thousands of USD 2022 Beginning defined benefit obligation as of January 1 14,936 Current service cost 718 Interest expense on defined benefit obligation 22 Contributions paid by employees 432 Benefits (paid)/deposited 1,041 Remeasurement (gain)/loss on defined benefit obligation (1,998 ) Other 5 Foreign currency exchange (gains)/losses (732 ) Ending defined benefit obligation as of June 30 14,424 Movements in the present value of the plan assets in the reporting period were as follows: In thousands of USD 2022 Beginning fair value of plan assets as of January 1 11,710 Return on plan assets excluding interest income 18 Contributions paid by employer 549 Contributions paid by employees 436 Benefits (paid)/deposited 1,041 Actuarial gain/(loss) on plan assets (1,168 ) Administration expense (2 ) Other (5 ) Foreign currency exchange gains/(losses) (591 ) Ending fair value of plan assets as of June 30 11,988
Disclosure of Plan Asset Allocation	The allocation of the assets of the different asset classes corresponds to: June 30, 2022 Cash 1.0 % Bonds 60.1 % Equities 25.7 % Properties 10.1 % Other 3.1 % Total 100.0 %
Disclosure of Defined Benefit Plan Actuarial Assumptions	Principal assumptions used for the purposes of the actuarial valuations were as follows: June 30, 2022 Discount rate 2.0 % Interest credit rate 2.0 % Expected rate of salary increase 2.0 % Expected rate of pension increase 0.0 % Mortality rate BVG 2020 GT

Financial Liabilities and Der_2

Financial Liabilities and Derivatives (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Liabilities and Derivatives [Abstract]
Schedule of Fair Value of the Warrants	The following assumptions were used to calculate the fair value of the warrants: Assumptions June 30, 2022 Expected volatility 64.8 % Expected term (in years) 6.7 Risk-free interest rate 2.3 % Dividiend yield 0.0 %

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Instrments [Abstract]
Financial Liabilities	As of June 30, 2022 In thousands of USD Financial assets and cash Financial Financial Total Financial assets 59 — — 59 Cash and cash equivalents 142,144 — — 142,144 Total financial assets 142,203 — — 142,203 Warrant liability — 1,124 — 1,124 Lease liabilities — — 221 221 Trade payables — — 12,527 12,527 Accrued expenses — — 14,944 14,944 Other current liabilities — — 1,445 1,445 Total financial liabilities — 1,124 29,137 30,261 As of December 31, 2021 In thousands of USD Financial assets and cash Financial Financial Total Financial assets 61 — — 61 Other current assets 4 — — 4 Cash and cash equivalents 102,707 — — 102,707 Total financial assets 102,772 — — 102,772 Lease liabilities — — 292 292 Trade payables — — 8,595 8,595 Accrued expenses — — 8,339 8,339 Total financial liabilities — — 17,226 17,226
Financial Assets	As of June 30, 2022 In thousands of USD Financial assets and cash Financial Financial Total Financial assets 59 — — 59 Cash and cash equivalents 142,144 — — 142,144 Total financial assets 142,203 — — 142,203 Warrant liability — 1,124 — 1,124 Lease liabilities — — 221 221 Trade payables — — 12,527 12,527 Accrued expenses — — 14,944 14,944 Other current liabilities — — 1,445 1,445 Total financial liabilities — 1,124 29,137 30,261 As of December 31, 2021 In thousands of USD Financial assets and cash Financial Financial Total Financial assets 61 — — 61 Other current assets 4 — — 4 Cash and cash equivalents 102,707 — — 102,707 Total financial assets 102,772 — — 102,772 Lease liabilities — — 292 292 Trade payables — — 8,595 8,595 Accrued expenses — — 8,339 8,339 Total financial liabilities — — 17,226 17,226

Related party transactions (Tab

Related party transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Related party transactions [abstract]
Disclosure of Transactions Between Related Parties	Compensation for Executive Management and Board of Directors (“BOD”) For the six-months ended June 30, In thousands of USD 2022 2021 Fees, salaries and other short-term employee benefits 2,519 1,912 Post-employment benefits 493 396 Share-based compensation 7,717 8,449 Total compensation for Executive Management and BOD 10,729 10,757

Organization and business (Deta

Organization and business (Details) $ / shares in Units, $ in Millions		6 Months Ended
	Apr. 09, 2021 USD ($) $ / shares shares	Jun. 30, 2022 segment shares	Jun. 30, 2021 shares
Disclosure of classes of share capital [line items]
Number of subsidiaries | segment		5
Ordinary shares
Disclosure of classes of share capital [line items]
Issuance of ordinary shares (in shares)		14,056,077	22,819,788
Ordinary shares | Initial Public Offering
Disclosure of classes of share capital [line items]
Issuance of ordinary shares (in shares)	8,625,000
Share price (in USD per share) | $ / shares	$ 17
Proceeds from issuing shares | $	$ 146.6

Significant changes in the cu_2

Significant changes in the current reporting period (Detail) $ / shares in Units, $ in Thousands

6 Months Ended

Jun. 27, 2022 shares

Jun. 23, 2022 USD ($) shares

Jun. 17, 2022 SFr / shares shares

Jun. 14, 2022 USD ($) $ / shares shares

Mar. 26, 2022 USD ($) tranche facility shares

Jun. 30, 2022 $ / shares shares

Jun. 30, 2021 shares

Jul. 04, 2022 $ / shares

Jul. 04, 2022 SFr / shares

Jun. 30, 2022 SFr / shares

Jun. 23, 2022 SFr / shares

Jun. 14, 2022 SFr / shares shares

May 06, 2022 SFr / shares

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Number of loan facilities | facility

2

Number of borrowing facility tranches | tranche

3

Par value per share | (per share)

$ 0.05

$ 0.05

SFr 0.05

SFr 0.05

SFr 0.05

Ordinary shares [member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Issuance of ordinary shares (in shares)

14,056,077

22,819,788

Underwriting Agreement [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Par value per share | SFr / shares

SFr 0.05

Increase (decrease) in number of ordinary shares issued

752,688

Underwriting Agreement [Member] | Ordinary shares [member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Par value per share | SFr / shares

SFr 0.05

Proceeds from issuing shares | $

$ 34,000

SVB Securities LLC and Piper Sandler Co [Member] | Underwriting Agreement [Member] | Ordinary shares [member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Common Stock Shares Subscribed But Not Issued

5,715,000

5,715,000

Par value per share | SFr / shares

SFr 0.05

SFr 0.05

Share price | $ / shares

$ 5.25

Increase (decrease) in number of ordinary shares issued

5,715,000

SVB Securities LLC and Piper Sandler Co [Member] | Underwriting Agreement [Member] | Additional Option To Acquire Shares From The Company [Member] | Ordinary shares [member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Common Stock Shares Subscribed But Not Issued

857,250

857,250

Par value per share | SFr / shares

SFr 0.05

SFr 0.05

Share price | $ / shares

$ 5.25

Period within which options granted shall be excercised

30 days

Proceeds from issuing shares | $

$ 34,000

Issuance of ordinary shares (in shares)

752,688

Forbion Growth Opportunities Fund II [Member] | Purchase Agreement [Member] | Ordinary shares [member] | Private Placement [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Par value per share | SFr / shares

SFr 0.05

Share price | $ / shares

$ 5.75

Increase (decrease) in number of ordinary shares issued

3,478,260

Proceeds from issuing shares | $

$ 20,000

Forbion Growth Opportunities Fund II [Member] | Purchase Agreement [Member] | Ordinary shares [member] | Authorized Capital [Member] | Private Placement [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Increase (decrease) in number of ordinary shares issued

425,252

Forbion Growth Opportunities Fund II [Member] | Purchase Agreement [Member] | Ordinary shares [member] | Treasury shares [member] | Private Placement [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Increase (decrease) in number of ordinary shares issued

3,053,008

the Loan [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Maximum borrowing capacity | $

$ 75,000

Debt issuance cost | $

$ 750

Warrant to purchase shares (in shares)

324,190

Warrant to purchase shares, value of shares | $

$ 1,000

Warrant to purchase shares, maximum exercise term

7 years

the Loan , Convertible Loan [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Maximum borrowing capacity | $

$ 18,750

the Loan , Term Loan [Member]

Disclosure Of Significant Changes In The Current Reporting Period [Line Items]

Maximum borrowing capacity | $

$ 56,250

Number of borrowing facility tranches | tranche

3

Summary of selected significa_4

Summary of selected significant accounting policies - Schedule of Initial Application of Standards or Interpretations (Details)	Jan. 01, 2022
Property, Plant and Equipment: Proceeds before intended use
Disclosure of initial application of standards or interpretations [line items]
Title	Amendments to IAS 16 – Property, Plant and Equipment: Proceeds before intended use
Effective Date	Jan. 01, 2022
Reference to the Conceptual Framework
Disclosure of initial application of standards or interpretations [line items]
Title	Amendments to IFRS 3 – Reference to the Conceptual Framework
Effective Date	Jan. 01, 2022
Onerous Contracts – Cost of Fulfilling a Contract
Disclosure of initial application of standards or interpretations [line items]
Title	Amendments to IAS 37 – Onerous Contracts – Cost of Fulfilling a Contract
Effective Date	Jan. 01, 2022
Annual Improvements to IFRS 9 Financial Instruments
Disclosure of initial application of standards or interpretations [line items]
Title	Annual Improvements to IFRS 9 Financial Instruments – clarifies which fees should be included in the 10% test for derecognition of financial liabilities.
Effective Date	Jan. 01, 2022
Annual Improvements to IFRS 16 Leases
Disclosure of initial application of standards or interpretations [line items]
Title	Annual Improvements to IFRS 16 Leases – amendment to remove any confusion about the treatment of lease incentives.
Effective Date	Jan. 01, 2022

Summary of selected significa_5

Summary of selected significant accounting policies - Narrative (Details) $ in Thousands	Mar. 26, 2022 USD ($) facility shares
Disclosure Of Significant Accounting Policies [Line Items]
Number of loan facilities | facility	2
the Loan
Disclosure Of Significant Accounting Policies [Line Items]
Maximum borrowing capacity	$ 75,000
Warrant to purchase shares (in shares) | shares	324,190
the Loan , Convertible Line
Disclosure Of Significant Accounting Policies [Line Items]
Maximum borrowing capacity	$ 18,750
the Loan , Term Loan
Disclosure Of Significant Accounting Policies [Line Items]
Maximum borrowing capacity	$ 56,250

Critical accounting judgments -

Critical accounting judgments - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Significant Accounting Estimates And Judgments [Line Items]
Net loss attributable to ordinary shareholders	$ 30,426	$ 45,118
Net cash used in operating activities	9,764	36,983
Cash and cash equivalents	142,144	$ 144,610	$ 102,707	$ 40,172
The Term Loan And The Convertible Loan A1 And A2 | The Loan tranches A1 and A2 [Member]
Significant Accounting Estimates And Judgments [Line Items]
Borowing facilities maximum borrowing capacity	50,000
The Term Loan And The Convertible Loan B | The Loan tranches B [Member]
Significant Accounting Estimates And Judgments [Line Items]
Borowing facilities maximum borrowing capacity	$ 25,000

Use of estimates in financial_2

Use of estimates in financial statement presentation - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Use Of Estimates In Financial Statement Presentation [Abstract]
Net pension liabilities	$ 2,436	$ 3,190

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Switzerland
Disclosure of geographical areas [line items]
Non-current non-financial assets	$ 22,713	$ 23,601
United States
Disclosure of geographical areas [line items]
Non-current non-financial assets	$ 2,788	$ 2,788

Revenue from contracts with c_2

Revenue from contracts with customers - Narrative (Details) $ in Thousands, ¥ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 30, 2022 USD ($)	Mar. 30, 2022 JPY (¥)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Upfront payment received			$ 24,610	¥ 3,000
Payment received for development activities			4,920	600
Additional payment received for development activities			8,200	1,000
Payment received for various milestones			164,060	20,000
Probability of transaction price for the performance obligations			37,740	4,600
Revenue from contracts with customers	$ 25,879
Development Milestones [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Payment received for various milestones			8,200	1,000
Regulatory Milestones [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Payment received for various milestones			24,610	3,000
Commercialization Milestones [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Payment received for various milestones			131,250	16,000
Intellectual Property License [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Transaction price allocated to remaining performance obligations			188,670	23,000
Revenue from contracts with customers	24,610
Development Services [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Transaction price allocated to remaining performance obligations			13,130	1,600
Probability of transaction price for the performance obligations			$ 13,130	¥ 1,600
Revenue from contracts with customers	$ 1,270

Research and development expe_3

Research and development expenses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	$ (37,511)	$ (26,494)
Employee expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	(8,233)	(6,177)
Services expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	(17,826)	(15,838)
Material expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	(7,906)	(2,237)
License and IP expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	(79)	(146)
Consulting expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	(3,394)	(1,143)
Change in contingent consideration liabilities
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	0	(860)
Depreciation and amortization expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	$ (73)	$ (93)

General and administrative ex_3

General and administrative expenses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	$ (19,290)	$ (19,097)
Employee expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(9,318)	(11,654)
Professional services expense
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(7,956)	(4,615)
Travel and meeting expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(304)	(17)
Facility expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(31)	(14)
Insurance and other charges expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(27)	(1)
Employee recruitment expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(160)	(1,071)
IT maintenance and support expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(835)	(448)
Capital tax and other non-income tax expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(78)	(826)
Depreciation and amortization expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	(48)	(58)
Office and other administrative expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expenses	$ (533)	$ (393)

Financial income and expense (D

Financial income and expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Financial Income And Expense [Abstract]
Interest income	$ 18
Financial income	18
Interest expense on lease liabilities	(1)	(1)
Kreos Loan facility fee expense	(556)
Other interest expenses and bank charges	(61)	(22)
Changes in fair value of Convertible loans	(4)
Financial expense	(622)	(23)
Foreign exchange differences, net	$ 1,126	$ 496

Share-based payments - Restrict

Share-based payments - Restricted Shares (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Restricted shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in (in shares)	0	0

Share-based payments - Share Op

Share-based payments - Share Options Narrative (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) shares plan	Jun. 30, 2021 USD ($) shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares) | shares	2,154,900	2,358,400
Expense from share-based payment transactions with employees	$ 9,412	$ 11,801
Number of shared based payment arrangement plans | plan	3
Related to research and development expenses
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense from share-based payment transactions with employees	$ 3,714	3,208
General and administrative expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense from share-based payment transactions with employees	$ 5,698	$ 8,593

Share-based payments - Share _2

Share-based payments - Share Options Fair Value Assumptions (Details)	6 Months Ended
	Jun. 30, 2022 yr $ / shares	Jun. 30, 2021 yr $ / shares
Share-Based Payment Arrangements [Abstract]
Fair value per share (in USD per share)	$ 3.89	$ 12.38
Exercise price (in USD per share)	$ 5.52	$ 4.7
Volatility	64.65%	58.10%
Duration | yr	10	10

Share-based payments - Share _3

Share-based payments - Share Options Activity (Details)	6 Months Ended
	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares
Average exercise price (USD) per share option
Options as of January 1 (in USD per share) | $ / shares	$ 3.32	$ 0.05
Granted during the year (in USD per share) | $ / shares	5.52	4.7
Forfeited during the year (in USD per share) | $ / shares	5.39	0.05
Outstanding as of June 30 (in USD per share) | $ / shares	4.07	3.09
Vested as of June 30 (in USD per share) | $ / shares	3.57	2.91
Exercisable as of June 30 (in USD per share) | $ / shares	$ 3.57	$ 2.91
Number of options
Options as of January 1 (in shares) | shares	3,847,800	1,252,900
Granted during the year (in shares) | shares	2,154,900	2,358,400
Forfeited during the year (in shares) | shares	(191,441)	(3,500)
Outstanding as of June 30 (in shares) | shares	5,811,259	3,607,800
Vested as of June 30 (in shares) | shares	1,219,631	182,677
Exercisable as of June 30 (in shares) | shares	1,219,631	182,677

Share-based payments - Share _4

Share-based payments - Share Options Outstanding (Details)	6 Months Ended
	Jun. 30, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares	Jun. 30, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.07	$ 3.32	$ 3.09	$ 0.05
Share options at June 30 (in shares) | shares	5,811,259	3,847,800	3,607,800	1,252,900
Weighted average fair value of options granted during the period (in USD per share) | $ / shares	$ 3.89
Weighted average remaining contractual life of outstanding share options	9 years 10 days
August 31, 2019
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	46,000
October 1, 2019
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	10,000
February 29, 2020
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	6,000
September 30, 2020
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	1,187,400
January 31, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	5,000
February 28, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	40,000
March 31, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 0.05
Share options at June 30 (in shares) | shares	60,000
April 30, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.8
Share options at June 30 (in shares) | shares	1,726,176
May 31, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.8
Share options at June 30 (in shares) | shares	428,600
June 30, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 11.66
Share options at June 30 (in shares) | shares	40,000
September 30, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 7.73
Share options at June 30 (in shares) | shares	160,000
September 30, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.8
Share options at June 30 (in shares) | shares	40,000
December 31, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.91
Share options at June 30 (in shares) | shares	40,000
January 31, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.83
Share options at June 30 (in shares) | shares	130,000
February 28, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 5.65
Share options at June 30 (in shares) | shares	1,610,483
March 31, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.71
Share options at June 30 (in shares) | shares	15,000
April 30, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 4.5
Share options at June 30 (in shares) | shares	110,000
May 31, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 5.84
Share options at June 30 (in shares) | shares	10,000
June 30, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price (in CHF per share) | $ / shares	$ 5.4
Share options at June 30 (in shares) | shares	146,600
June 30, 2022 Total [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share options at June 30 (in shares) | shares	5,881,259

Share-based payments - Restri_2

Share-based payments - Restricted Share Units Narrative (Details) - Restricted Share Units (RSU) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments granted in (in shares)	0	446,000
Number of other equity instruments forfeited (in shares)	30,000	0
Number of other equity instruments settled (in shares)	118,355,000	0
Tax withheld | $	$ 250

Share-based payments - Restri_3

Share-based payments - Restricted Share Units Activity (Details) - Restricted Share Units (RSU)	6 Months Ended
	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares
Restricted share units
RSUs as of January 1 (in shares) | shares	548,969	234,500
Granted during the year (in shares) | shares	0	446,000
Vested or expected to vest (in shares) | shares	(141,212)	(25,761)
Forfeited during the year (in shares) | shares	(30,000)	0
Non-vested RSUs as of June 30 (in shares) | shares	377,757	654.739
Weighted- average grant date fair value
RSUs as of January 1 (in USD per share) | $ / shares	$ 11.86	$ 4.6
Granted during the year (in USD per share) | $ / shares	0	15.55
Vested or expected to vest (in USD per share) | $ / shares	12.45	5.18
Forfeited during the year (in USD per share) | $ / shares	15.55	0
Non-vested RSUs as of June 30 (in USD per share) | $ / shares	$ 11.35	$ 12.04

Loss per share - Schedule of Lo

Loss per share - Schedule of Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Earnings per share [abstract]
Net loss attributable to ordinary shareholders	$ (30,426)	$ (45,118)
Weighted average number of ordinary shares issued and outstanding, basic (in shares)	35,555,929	19,977,608
Weighted average number of ordinary shares issued and outstanding, diluted (in shares)	35,555,929	19,977,608
Basic loss per share (in USD per share)	$ (0.86)	$ (2.26)
Diluted loss per share (in USD per share)	$ (0.86)	$ (2.26)

Loss per share - Narrative (Det

Loss per share - Narrative (Details) - shares	Jun. 30, 2022	Jun. 30, 2021
Earnings per share [abstract]
Number of shares issued but not yet vested (in shares)	805,106	1,957,032
Number of shares not issued but vested (in shares)	9,989	23,261

Goodwill and intangible asset_2

Goodwill and intangible assets - Schedule of Goodwill and Intangible Assets (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	$ 26,047
Product intangibles: not available for use	0
Retirements	0
Foreign exchange difference	(782)
Intangible assets and goodwill at end of period	25,265
Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	925
Product intangibles: not available for use	0
Retirements	0
Foreign exchange difference	(31)
Intangible assets and goodwill at end of period	894
Apraglutide
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	22,334
Product intangibles: not available for use	0
Retirements	0
Foreign exchange difference	(751)
Intangible assets and goodwill at end of period	21,583
Comet Platform
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	2,788
Product intangibles: not available for use	0
Retirements	0
Foreign exchange difference	0
Intangible assets and goodwill at end of period	$ 2,788

Share capital - Classes of Shar

Share capital - Classes of Shares Outstanding (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Nominal value of shares
Balance at beginning of year	$ 115,999	$ 32,238
Share capital increase (Note 18)	53,955	154,125
Total balance at end of the year	141,826	140,402
Share capital
Nominal value of shares
Balance at beginning of year	1,935	1,409
Total balance at end of the year	$ 2,661	$ 1,895
Ordinary shares
Number of issued and outstanding shares
Balance at beginning of year (in shares)	36,635,713	13,042,080
Issuance of ordinary shares (in shares)	14,056,077	22,819,788
Balance at the end of the year (in shares)	50,691,790	35,861,868
Ordinary shares | Share capital
Nominal value of shares
Share capital increase (Note 18)	$ 726	$ 486

Share capital - Issued Share Ca

Share capital - Issued Share Capital Narrative (Details)				6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 23, 2022 USD ($)	Jun. 17, 2022 SFr / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) shares	Jul. 04, 2022 $ / shares	Jul. 04, 2022 SFr / shares	Jun. 30, 2022 CHF (SFr) SFr / shares shares	Jun. 27, 2022 shares	Jun. 23, 2022 SFr / shares	May 06, 2022 SFr / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 CHF (SFr) shares	Dec. 31, 2020 USD ($)
Disclosure of classes of share capital [line items]
Equity | $	$ 141,826,000			$ 141,826,000	$ 140,402,000							$ 115,999,000		$ 32,238,000
Par value per share (in CHF/USD per share) | (per share)	$ 0.05			$ 0.05		$ 0.05	SFr 0.05	SFr 0.05			SFr 0.05
Transaction costs due to capital increase | $				$ 4,496,000	13,039,000
Forbion Growth Opportunities Fund II [Member]
Disclosure of classes of share capital [line items]
Par value per share (in CHF/USD per share) | SFr / shares								SFr 0.05
Number Of Shares Issued	3,478,260			3,478,260				3,478,260
Share price (in USD per share) | $ / shares	$ 5.75			$ 5.75
Underwriting Agreement [Member]
Disclosure of classes of share capital [line items]
Par value per share (in CHF/USD per share) | SFr / shares										SFr 0.05
Increase Decrease In Number Of Ordinary Shares Issued			752,688
Ordinary shares
Disclosure of classes of share capital [line items]
Number of shares outstanding (in shares)	46,037,642			46,037,642				46,037,642				35,973,339	35,973,339
Number Of Shares Issued	4,110,129			4,110,129				4,110,129			3,053,008
Ordinary shares | Forbion Growth Opportunities Fund II [Member]
Disclosure of classes of share capital [line items]
Proceeds from issuing shares | $	$ 20,000,000
Number Of Shares Issued	3,478,260			3,478,260				3,478,260
Ordinary shares | Underwriting Agreement [Member]
Disclosure of classes of share capital [line items]
Par value per share (in CHF/USD per share) | SFr / shares			SFr 0.05
Proceeds from issuing shares | $		$ 34,000,000
Number Of Shares Issued			5,715,000
Share capital
Disclosure of classes of share capital [line items]
Equity	$ 2,661,000			$ 2,661,000				SFr 2,534,589.5				$ 1,935,000	SFr 1,831,785.65
Authorized Capital [Member] | Ordinary shares | Forbion Growth Opportunities Fund II [Member] | Private Placement [Member]
Disclosure of classes of share capital [line items]
Number Of Shares Issued	425,252			425,252				425,252
Treasury shares [member]
Disclosure of classes of share capital [line items]
Equity | $	$ (581,000)			$ (581,000)	$ (39,000)							$ (35,000)		$ (39,000)
Number of shares outstanding (in shares)	4,654,148			4,654,148				4,654,148				662,374	662,374
Number Of Shares Issued	162,707			162,707				162,707
Number of other equity instruments settled (in shares)				44,352	0
Treasury shares [member] | Ordinary shares | Forbion Growth Opportunities Fund II [Member] | Private Placement [Member]
Disclosure of classes of share capital [line items]
Number Of Shares Issued									3,053,008

Share capital - Schedule of Tre

Share capital - Schedule of Treasury Shares (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Nominal value of shares
Balance at beginning of year	$ 115,999	$ 32,238
Employee share-based payment issue	9,412	11,801
Shares issued but not granted	53,955	154,125
Total balance at end of the year	$ 141,826	140,402
Treasury shares
Number of issued and outstanding shares
Balance at beginning of year (in shares)	(662,374)
Employee share-based payment issue (inn shares)	118,355
Treasury shares (in shares)	(4,110,129)
Balance at end of the year (in shares)	(4,654,148)
Nominal value of shares
Balance at beginning of year	$ (35)	(39)
Employee share-based payment issue	(331)
Shares issued but not granted	(215)
Total balance at end of the year	$ (581)	$ (39)

Share capital - Authorized Shar

Share capital - Authorized Share Capital Narrative (Details) SFr / shares in Units, $ / shares in Units, $ in Thousands	Jun. 30, 2022 USD ($) $ / shares shares	Jul. 04, 2022 SFr / shares	Jul. 04, 2022 $ / shares	Jun. 30, 2022 CHF (SFr) SFr / shares shares	May 06, 2022 SFr / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 CHF (SFr) shares	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disclosure of classes of share capital [line items]
Equity | $	$ 141,826					$ 115,999		$ 140,402	$ 32,238
Par value per share (in CHF/USD per share) | (per share)	$ 0.05	SFr 0.05	$ 0.05	SFr 0.05	SFr 0.05
Ordinary shares
Disclosure of classes of share capital [line items]
Number of shares authorized (in shares)	1,817,923			1,817,923		15,874,000	15,874,000
Authorized share capital
Disclosure of classes of share capital [line items]
Equity	$ 95			SFr 90,896.15		$ 860	SFr 793,700
Increase Decrease Number Of Ordinary Shares Issued value	$ 1,038			SFr 992,218,000
Authorized share capital | Ordinary shares
Disclosure of classes of share capital [line items]
Par value per share (in CHF/USD per share) | (per share)	$ 0.05			SFr 0.05
Increase Decrease In Number Of Ordinary Shares Issued	19,844,360

Share capital - Conditional Sha

Share capital - Conditional Share Capital Narrative (Details) SFr / shares in Units, $ / shares in Units, $ in Thousands	Jul. 04, 2022 CHF (SFr) SFr / shares shares	Jun. 30, 2022 CHF (SFr) SFr / shares shares	Jul. 04, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($) $ / shares shares	May 06, 2022 SFr / shares	Dec. 31, 2021 CHF (SFr) shares	Dec. 31, 2021 USD ($) shares
Disclosure of classes of share capital [line items]
Temporary equity, carrying amount		SFr 832,392.25		$ 871		SFr 832,392.25	$ 973
Par value per share (in CHF/USD per share) | (per share)	SFr 0.05	SFr 0.05	$ 0.05	$ 0.05	SFr 0.05
Ordinary shares
Disclosure of classes of share capital [line items]
Temporary equity, shares outstanding (in shares)		16,647,845		16,647,845		16,647,845	16,647,845
Conditional Share Capital [Member]
Disclosure of classes of share capital [line items]
Par value per share (in CHF/USD per share) | (per share)		SFr 0.05		$ 0.05
Increase Decrease Number Of Ordinary Shares Issued value	SFr 992,218	SFr 541,332	$ 1,038	$ 567
Increase Decrease In Number Of Ordinary Shares Issued	19,844,360	10,826,640

Defined benefit plan - Narrativ

Defined benefit plan - Narrative (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	25%
(Decrease) increase in defined benefit obligation due to reasonably possible increase in actuarial assumption	$ 59
Weighted average duration of defined benefit obligation	15 years
Estimate of contributions expected to be paid to plan for next annual reporting period	$ 370
Actuarial assumption of discount rates
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible decrease in actuarial assumption	25%
(Decrease) increase in defined benefit obligation due to reasonably possible increase in actuarial assumption	$ 283
Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption	298
Actuarial assumption of expected rates of salary increases
Disclosure of defined benefit plans [line items]
Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption	$ 59
Actuarial assumption of expected rates of pension increases
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	25%
(Decrease) increase in defined benefit obligation due to reasonably possible increase in actuarial assumption	$ 230

Defined benefit plan - Expense

Defined benefit plan - Expense Recognized in Profit Or Loss (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of defined benefit plans [abstract]
Current service cost	$ 718	$ 370
Interest cost	22	8
Expected return on plan assets	(18)	(7)
Administration costs	2	3
Expense recognized in profit or loss	$ 724	$ 374

Defined benefit plan - Expens_2

Defined benefit plan - Expense Recognized in OCI (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Remeasurement (gain)/loss on defined benefit obligation
Actuarial (gains)/losses arising from plan experience	$ 1,215	$ 264
Actuarial (gains)/losses arising from demographic assumption	0	(570)
Actuarial (gains)/losses arising from financial assumptions	(3,213)	(310)
Return on plan assets excl. interest income	1,168	108
Expense recognized in other comprehensive income	$ (830)	$ (508)

Defined benefit plan - Net Defi

Defined benefit plan - Net Defined Benefit Obligation (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of net defined benefit liability (asset) [line items]
Net liability arising from defined benefit obligation	$ 2,436
Present value of defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net liability arising from defined benefit obligation	14,424	$ 14,936
Fair value of plan assets
Disclosure of net defined benefit liability (asset) [line items]
Net liability arising from defined benefit obligation	$ 11,988	$ 11,710

Defined benefit plan - Movement

Defined benefit plan - Movement in Defined Benefit Obligation (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Disclosure of net defined benefit liability (asset) [line items]
Ending defined benefit obligation as of June 30	$ 2,436
Present value of defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Beginning defined benefit obligation as of January 1	14,936
Current service cost	718
Interest expense on defined benefit obligation	22
Contributions paid by employees	432
Benefits (paid)/deposited	1,041
Remeasurement (gain)/loss on defined benefit obligation	(1,998)
Other	5
Foreign currency exchange (gains)/losses	(732)
Ending defined benefit obligation as of June 30	$ 14,424

Defined benefit plan - Moveme_2

Defined benefit plan - Movement in Plan Assets (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Disclosure of net defined benefit liability (asset) [line items]
Ending defined benefit obligation as of June 30	$ 2,436
Fair value of plan assets
Disclosure of net defined benefit liability (asset) [line items]
Beginning defined benefit obligation as of January 1	11,710
Return on plan assets excluding interest income	18
Contributions paid by employer	549
Contributions paid by employees	436
Benefits (paid)/deposited	1,041
Actuarial gain/(loss) on plan assets	(1,168)
Administration expense	(2)
Other	(5)
Foreign currency exchange (gains)/losses	(591)
Ending defined benefit obligation as of June 30	$ 11,988

Defined benefit plan - Allocati

Defined benefit plan - Allocation of Plan Assets (Details)	Jun. 30, 2022
Disclosure of defined benefit plans [abstract]
Cash	1%
Bonds	60.10%
Equities	25.70%
Properties	10.10%
Other	3.10%
Total	100%

Defined benefit plan - Actuaria

Defined benefit plan - Actuarial Assumptions (Details)	6 Months Ended
	Jun. 30, 2022
Disclosure of defined benefit plans [abstract]
Discount rate	2%
Interest credit rate	2%
Expected rate of salary increase	2%
Expected rate of pension increase	0%

Financial Liabilities and Der_3

Financial Liabilities and Derivatives - Schedule of Fair Value of the Warrants (Detail)	Jun. 30, 2022 yr
Expected Volatility [Member]
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Significant unobservable input, liabilities	64.8
Expected term (in years) [Member]
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Significant unobservable input, liabilities	6.7
Risk Free Interest Rate [Member]
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Significant unobservable input, liabilities	2.3
Dividiend Yield [Member]
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Significant unobservable input, liabilities	0

Financial Liabilities and Der_4

Financial Liabilities and Derivatives (Details) $ / shares in Units, $ in Thousands		6 Months Ended
	Mar. 26, 2022 USD ($) tranche facility $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Number of loan facilities | facility	2
Number of borrowing facility tranches | tranche	3
Transactions Fees		$ 750
Financial expenses		622	$ 23
Proceeds from current borrowings		100
Cash flows from (used in) maintaining operating capacity		650
Warrants exercise price | $ / shares	$ 5.5243
Fair value of warrants	$ 1,120	1,124
Class of warrant or right transaction fee expense recognized		333
Change in fair value of warrants		$ 4
Loan A1 Convertible Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	7,500
Loan A1 Term Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	22,500
Loan A2 Convertible Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	5,000
Loan A2 Term Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	15,000
Loan B Convertible Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	6,250
Loan B Term Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	18,750
Loan A1 [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowing Facilities, Current Borrowing Capacity				$ 10,000
Loan A2 [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowing Facilities, Current Borrowing Capacity				$ 2,500
The Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	$ 75,000
Warrant to purchase shares (in shares) | shares	324,190
Warrant to purchase shares, value of shares	$ 1,000
Warrant to purchase shares, maximum exercise term	7 years
The Loan , Convertible Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	$ 18,750
The Loan , Term Loan [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Maximum borrowing capacity	$ 56,250
Number of borrowing facility tranches | tranche	3
Maximum debt-to-market-cap ratio	25%
Borrowings, interest rate		8.95%
Loans draw down		$ 0
Borrowings		0
the Loan, Term Loan, Loan B [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Minimum equity, subordinated convertible debt or other non-dilutive funds to be raised	$ 80,000
Convertible Loans [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowing Facilities, Current Borrowing Capacity		0
Financial expenses		223
Convertible loans at fair value		$ 0
Borrowings, interest rate		7.45%
Borrowings early repayment annual discount rate per annum		4%
Borrowings early repayment percentage of principal amount repaid		101%
Borrowings early repayment percentage of addiitonal payments on debt drawn		3%
Convertible Loans [Member] | Bottom of range [member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowings, repayment period		12 months
Convertible Loans [Member] | Top of range [member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowings, repayment period		37 months
Convertible Loans [Member] | Borrowings Extension Clause One [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowings Extension Option Date		Dec. 31, 2025
Threshold minimum proceeds from issuance of equity or debt		$ 80,000
Convertible Loans [Member] | Borrowings Extension Clause Two [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Borrowings Extension Option Date		Jun. 30, 2026
Minimum Convertible Note [Member]
Disclosure Of Financial Liabilities And Derivatives [Line Items]
Number of shares issued in conversion (in shares) | shares		356,961
Conversion price per share (in USD per share) | $ / shares		$ 7.0036
Share premium percentage in determining share price		130%
Number of trading days		30 days

Financial instruments - Categor

Financial instruments - Categories of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [line items]
Financial assets	$ 142,203	$ 102,772
Financial liabilities	30,261	17,226
Warrant liability
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,124
Lease liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	221	292
Trade payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	12,527	8,595
Accrued expenses
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	14,944	8,339
Other current liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,445
Financial liabilities at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,124	0
Financial liabilities at fair value through profit or loss | Warrant liability
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,124
Financial liabilities at fair value through profit or loss | Lease liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities at fair value through profit or loss | Trade payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities at fair value through profit or loss | Accrued expenses
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities at fair value through profit or loss | Other current liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0
Financial liabilities at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	29,137	17,226
Financial liabilities at amortized cost | Warrant liability
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0
Financial liabilities at amortized cost | Lease liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	221	292
Financial liabilities at amortized cost | Trade payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	12,527	8,595
Financial liabilities at amortized cost | Accrued expenses
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	14,944	8,339
Financial liabilities at amortized cost | Other current liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,445
Financial assets at amortized cost (incl. Cash and cash equivalents)
Disclosure of detailed information about financial instruments [line items]
Financial assets	142,203	102,772
Financial assets
Disclosure of detailed information about financial instruments [line items]
Financial assets	59	61
Financial assets | Financial assets at amortized cost (incl. Cash and cash equivalents)
Disclosure of detailed information about financial instruments [line items]
Financial assets	59	61
Other current assets
Disclosure of detailed information about financial instruments [line items]
Financial assets		4
Other current assets | Financial assets at amortized cost (incl. Cash and cash equivalents)
Disclosure of detailed information about financial instruments [line items]
Financial assets		4
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Financial assets	142,144	102,707
Cash and cash equivalents | Financial assets at amortized cost (incl. Cash and cash equivalents)
Disclosure of detailed information about financial instruments [line items]
Financial assets	$ 142,144	$ 102,707

Related party transactions -Com

Related party transactions -Compensation for Executive Management and Board of Directors (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Related party transactions [abstract]
Fees, salaries and other short-term employee benefits	$ 2,519	$ 1,912
Post-employment benefits	493	396
Share-based compensation	7,717	8,449
Total compensation for Executive Management and BOD	$ 10,729	$ 10,757

Contract Balances - Narrative (

Contract Balances - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Contract liabilities [abstract]
Contract liabilities	$ 3,488	$ 0

Events after reporting period (

Events after reporting period (Details) SFr in Thousands, $ in Thousands	May 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Oct. 12, 2022 USD ($) facility	Jul. 04, 2022 USD ($)	Jul. 04, 2022 CHF (SFr)	Mar. 26, 2022 USD ($) facility
Disclosure of detailed information about borrowings [line items]
Number of loan facilities | facility						2
Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Number of loan facilities | facility			2
Entering into borrowing commitments | Comet Therapeutics Inc. [Member]
Disclosure of detailed information about borrowings [line items]
Identifiable assets acquired (liabilities assumed)				$ 6,430	SFr 5,860
the Loan
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity						$ 75,000
the Loan | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			$ 75,000
the Loan , Convertible Line
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity						18,750
the Loan , Convertible Line | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			18,750
the Loan , Term Loan
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity						56,250
the Loan , Term Loan | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			56,250
Loan A [Member] | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Undrawn borrowing facilities	$ 10,000	$ 10,000
Loan A Convertible Loan [Member] | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			12,500
Loan A Term Loan [Member] | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			37,500
Loan B Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity						6,250
Loan B Convertible Loan [Member] | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			6,250
Loan B Term Loan [Member]
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity						$ 18,750
Loan B Term Loan [Member] | Entering into borrowing commitments
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity			$ 18,750